International Journal of Medicinal Chemistry

International Journal of Medicinal Chemistry / 2015 / Article

Review Article | Open Access

Volume 2015 |Article ID 430248 | https://doi.org/10.1155/2015/430248

Terry Clayton, Michael M. Poe, Sundari Rallapalli, Poonam Biawat, Miroslav M. Savić, James K. Rowlett, George Gallos, Charles W. Emala, Catherine C. Kaczorowski, Douglas C. Stafford, Leggy A. Arnold, James M. Cook, "A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model", International Journal of Medicinal Chemistry, vol. 2015, Article ID 430248, 54 pages, 2015. https://doi.org/10.1155/2015/430248

A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model

Academic Editor: Hussein El-Subbagh
Received11 Feb 2015
Revised16 Jun 2015
Accepted02 Jul 2015
Published10 Nov 2015

Abstract

An updated model of the GABA(A) benzodiazepine receptor pharmacophore of the α5-BzR/GABA(A) subtype has been constructed prompted by the synthesis of subtype selective ligands in light of the recent developments in both ligand synthesis, behavioral studies, and molecular modeling studies of the binding site itself. A number of BzR/GABA(A) α5 subtype selective compounds were synthesized, notably α5-subtype selective inverse agonist PWZ-029 (1) which is active in enhancing cognition in both rodents and primates. In addition, a chiral positive allosteric modulator (PAM), SH-053-2′F-R-CH3 (2), has been shown to reverse the deleterious effects in the MAM-model of schizophrenia as well as alleviate constriction in airway smooth muscle. Presented here is an updated model of the pharmacophore for α5β2γ2 Bz/GABA(A) receptors, including a rendering of PWZ-029 docked within the α5-binding pocket showing specific interactions of the molecule with the receptor. Differences in the included volume as compared to α1β2γ2, α2β2γ2, and α3β2γ2 will be illustrated for clarity. These new models enhance the ability to understand structural characteristics of ligands which act as agonists, antagonists, or inverse agonists at the Bz BS of GABA(A) receptors.

1. Introduction

The gamma-amino butyric acid A () receptor is a heteropentameric chloride ion channel. This channel is generally made up of two α-subunits, two β-subunits, and a single γ-subunit arranged in an αβαβγ fashion. The receptors (R) are responsible for a myriad of brain functions. Positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) act on the benzodiazepine (BZ) site of the R which can change the conformation of the receptor to inhibit or excite the neurons associated with the ion channel. To date, researchers have been unable to get an X-ray crystal structure of a functional Bz/R ion channel. Recently, Miller and Aricescu [1] have reported the crystal structure of a homopentameric R containing the β3-subunit at 3 Å resolution. Although this work provides great promise that other heteropentameric Rs will be crystallized in the near future, molecular modeling and structure-activity-relationships (SARs) still remain key tools to find better subtype-selective binding agents.

2. Subtype Selective Ligands for α5 GABA(A)/Bz Receptors

Interest in BzR/GABA(A) α5 subtypes began years ago when it was realized that α5β3γ2 Bz/GABA(A) subtypes are located primarily in the hippocampus. More recently this interest has been confirmed by the report of Möhler et al. [25] on α5 “knock-in mice.” This group has provided strong evidence that hippocampal extrasynaptic α5 GABA(A) receptors play a critical role in associative learning as mentioned above [611].

Earlier we synthesized a series of α5 subtype selective ligands (RY-023, RY-024, RY-079, and RY-080) based on the structure of Ro 15-4513 and reported their binding affinity [6], as well as several ligands by Atack et al. [12]. These ligands are benzodiazepine receptor (BzR) negative modulators in vivo and a number of these compounds have been shown to enhance memory and learning [13]. One of these ligands was shown by Bailey et al. [6] to be important in the acquisition of fear conditioning and has provided further evidence for the involvement of hippocampal GABA(A)/BzR in learning and anxiety [13]. This is in agreement with the work of DeLorey et al. [7] in a memory model with a ligand closely related to α5 subtype selective inverse agonists RY-024 and RY-079 including PWZ-029 (1).

In order to enhance the α5 subtype selectivity, the bivalent form of RY-80 (3) was prepared to provide XLi-093 (4) [13]. The binding affinity of XLi-093 in vitro was determined on β3γ2 LTK cells and is illustrated in Figure 1. This bivalent ligand exhibited little or no affinity at β3γ2 BzR/GABA(A) subtypes, but this α5 ligand had a of 15 nM at the α5β3γ2 subtype [14]. Since this receptor binding study indicated bivalent ligand XLi-093 bound almost exclusively to the α5 subtype, the efficacy of this ligand on GABA(A) receptor subtypes expressed in Xenopus oocytes was investigated by Sieghart, Furtmueller, Li, and Cook [14, 15]. Analysis of the data indicated that XLi-093 up to a concentration of 1 μM did not trigger chloride flux in any one of the GABA(A) subtypes tested. At 1 μM XLi-093 did not modulate GABA induced chloride flux in α1β3γ2, α2β3γ2, or α3β3γ2 receptors, but very slightly inhibited chloride flux in α5β3γ2 subtypes. At 1 μM, XLi-093 barely influenced benzodiazepine (Valium) stimulation of GABA-induced current in α1β3γ2, α2β3γ2, and α3β3γ2 BzR but shifted the diazepam dose response curve to the right in α5β3γ2 receptors in a very significant manner [16]. Importantly, bivalent ligand XLi-093 was able to dose dependently and completely inhibit diazepam-stimulated currents in α5β3γ2 receptors. This was the first subtype selective benzodiazepine receptor site antagonist at α5 receptors. This bivalent ligand XLi-093 provided a lead compound for all of the bivalent ligands in this research [16].

Illustrated in Figure 2 is XLi-093 (4) aligned excellently within the pharmacophore-receptor model of the α5β3γ2 subtype [14, 1619]. The fit to the pharmacophore-receptor and the binding data indicate that bivalent ligands will bind to BzR subtypes [14, 19]. It is believed that the dimer enters the binding pocket with one monomeric unit docking while the other monomer tethered by a linker extends out of the protein into the extracellular domain. If this is in fact true that the second imidazole unit is protruding into the extracellular domain of the BzR/GABA(A) α5 binding site, it could have a profound effect on the ligand design. This means other homodimers or even heterodimers may bind to BzR/GABA(A)ergic sites.

In this vein, Wenger, Li, and Cook et al. [13, 20, 21] earlier described preliminary data that XLi-093, an α5 subtype selective antagonist, enhances performance of C57BL/6J mice under a titrating delayed matching to position schedule of cognition, as illustrated in Figure 3 [14, 1619]. This indicates, however, that this agent does cross the blood brain barrier.

Bivalent ligands have a preferred linker of 3–5 methylene units, between the two pharmacophores (see XLi-093). This was established by NMR experiments run at low temperatures, X-ray crystallography, and molecular modeling of the ligands in question and will be discussed [14, 17, 18].

Based on this data, additional α5-subtype selective ligands have been prepared (see Figure 4). The basic imidazobenzodiazepine structure has been maintained [7]; however substituents were varied in regions around the scaffold based on molecular modeling [6]. These are now the most α5 subtype selective ligands ever reported [22]. Moreover, the ability to increase the subtype selectivity can be done by selecting specific substituents on these ligands to new agents with 400–1000-fold α5-selectivity over the remaining 5 subtypes. This is an important step forward to understanding the true, unequivocal physiological responses mediated by α5 subtypes in regard to cognition (amnesia), schizophrenia, anxiety, and convulsions, all of which in some degree are influenced by α5 subtypes. Based on the ligands in Figures 4 and 5, affinity has occurred principally at α5 subtypes. In addition, since XLi-093 bound very tightly only to α5 BzR subtypes, the bivalent nature and functionality presented here can be incorporated into other dimeric ligands.

As shown previously in Figure 3, α5-antagonist XLi-093 (4) was shown to enhance cognition. In another study, a reduction of the two acetylenic groups of XLi-093 resulted in ethyl groups [14], providing a new bivalent ligand (XLi-356, 10) which shows α5-selective binding with very low affinity for α1 subtypes (Figure 5). Efficacy (oocyte) data shows XLi-356 is an α5 negative allosteric modulator [7, 13]. DeLorey et al. have recently shown in mice that XLi-356 does potently reverse scopolamine induced memory deficits [7]. This bivalent α5 inverse agonist enhanced cognition in agreement with work reported from our laboratory on monovalent inverse agonists RY-10 [6] and RY-23 [7].

The dimers XLi-093 (4) and XLi-356 (10) were sent to Case Western Reserve (NIMH supported PDSP program, Roth et al.) for full panel receptor binding and they do not bind to other receptors at levels of concern (Table 1).


Cook code5ht1a5ht1b5ht1d5ht1e5ht2a5ht2b5ht2c5ht35ht5a5ht65ht7α1Aβ1Bα2Aα2B

XLi093Repeat
XLi356

Cook code2CBeta1Beta2CB1CB2D1D2D3D4D5DATDORH1H2H3

XLi093
XLi356

Cook codeH4Imidaz oline KORM1M2M3M4M5MDR MORNETNMDASERT12

XLi0932,024.00
XLi3566,118.00

Data (“secondary binding”) are values. values are reported in nanomolar concentration, Case Western Reserve University. “” indicates “primary missed” (<50% inhibition at 10 µM). See full data of the PDSP screen in the report of Clayton [22].

Although XLi-093 (4) was found to be an antagonist at the α5 subtype, XLi-356 (10) was found to be a weak agonist-antagonist. XLi-356 was found to reverse scopolamine induced memory deficits in mice. When XLi-356 was looked at in audio cued fear conditioning, the results show no activity. This suggests that the effect of XLi-356 is selective through α5 receptors which are abundant in the hippocampus which is highly associated with contextual memory. Audio cued memory instead is amygdala-based and should not be affected by an α5 subtype selective compound [3942].

As illustrated in Figure 6, scopolamine (1 mg/kg) reduced freezing (i.e., impairs memory) generally due to coupling the context (the cage) with a mild shock. XLi-356 (10 mg/kg) attenuated the impairment of memory returning the freezing to the levels on par with subjects dosed with vehicle. In audio cued memory the response was activated by sound, not the context. XLi-356 was not able to reverse this type of memory effect which is amygdala driven. A similar effect was observed for XLi-093 by Harris et al. [43]. XLi-093 is the most selective antagonist for α5 subtypes reported to date [13, 43] and is a very useful α5 antagonist used by many in vivo [22, 44, 45].

Molecular modeling combined with this knowledge was used to generate new lead compounds aimed at the development of α5-subtype selective positive and negative allosteric modulators to study cognition as well as amnesia mediated by the hippocampus. All of these compounds have been prepared based on the structure of current α5-subtype selective ligands synthesized in Milwaukee [46] (see Figures 4 and 5), as well as the binding affinity (15 nM)/selectivity of bivalent α5 antagonist XLi-093 (4) [13].

In efforts to enhance α5-selectivity in regards to cognition, Cook, Bailey, and Helmstetter et al. have employed RY-024 to study the hippocampal involvement in the benzodiazepine receptor in learning and anxiety [14, 19]. Supporting this Harris, DeLorey et al. show in mice that α5 NAMs (1) and RY-10 potently reversed scopolamine-induced memory impairment. These α5 NAMs provide insight as to how Rs influence contextual memory, an aspect of memory affected in age associated memory impairment and especially in Alzheimer’s disease [13, 6264]. In addition, Savić et al. have used the α1 preferring antagonist, BCCt, in passive avoidance studies, in which midazolam’s amnesic effects are shown to be due to interaction of agonist ligands at α5 in addition to α1β3γ2 BzR subtypes [24, 65].

3. PWZ-029: A Negative Allosteric Modulator

PWZ-029 (1) has been studied extensively as an α5-R inverse agonist and in certain experimental models has been shown to enhance cognition. The binding data from three separate laboratories (Table 2) have all shown that it exhibits remarkable selectivity for the α5 subunit-containing receptors, all greater than 60-fold compared to the next subunit.


CodeMWα1α2α3α4α5α6

PWZ-029 (1)291.73>300>300>300ND38.8>300
PWZ-029 (1)291.73920NDNDND30ND
PWZ-029 (1)291.73362180328ND6ND

Data from three separate laboratories.

Electrophysiological efficacy testing done by Sieghart et al. in oocytes demonstrated that PWZ-029 (1) acts as a negative allosteric modulator at the α5-subunit, with a very weak agonist activity at the α1, α2, and α3 subunits (Figure 7). At a pharmacologically relevant concentration of 0.1 μM, PWZ-029 exhibits moderate negative modulation at the α5-subunit, while showing little or no effect at the α1, α2, or α3-subunits.

Milić et al. reported on the effects of PWZ-029 in the widely used novel object recognition test, which differentiates between the exploration time of novel and familiar objects. As shown by significant differences between the exploration times of the novel and familiar object (Figure 8(a)), as well as the respective discrimination indices (Figure 8(b)), all the three tested doses of PWZ-029 (2, 5 and 10 mg/kg) improved object recognition in rats after the 24 h delay period. Additionally, in the procedure with the 1 h delay between training and testing, the lowest of the tested doses of PWZ-029 (2 mg/kg) successfully reversed the deficit in recognition memory induced by 0.3 mg/kg scopolamine (Figure 9) [25].

The results of the described study showed for the first time that inverse agonism at α5- receptors may be efficacious in both improving cognitive performance in unimpaired subjects and ameliorating cognitive deficits in pharmacologically impaired subjects, as assessed in two protocols of the same animal model [25].

In a recent by Rowlett et al. [26], negative allosteric modulator PWZ-029 was evaluated in female rhesus monkeys () in an Object Retrieval test with Detours (ORD; Figure 10 for details). 1 was administered via i.v. catheters in ORD trained monkeys and evaluated for cognition enhancement. A successful trial was determined by the ability of the subject to obtain a food reward within a transparent box with a single open side, with varying degrees of difficulty (“easy” or “difficult” or “mixed” as a combination of both) based on food placement within the box. In “mixed” trials using PWZ-029, no significant results were observed when compared to vehicle (Figure 11(a)). “Difficult” trials, however, exhibited an increasing dose-dependent curve for successful trials (Figure 11(b)). These results were attenuated by a coadministration α5-antagonist XLi-093 (Figure 11(c)). PWZ-029 was also shown to dose-dependently reverse the cholinergic deficits that were induced by scopolamine (Figure 11(d)) [26].

These findings suggest that PWZ-029 can enhance performance on the ORD task, only under conditions in which baseline performance is attenuated. The effects of PWZ-029 were antagonized in a surmountable fashion by the selective α5- ligand, XLi-093, consistent with PWZ-029’s effects being mediating via the α5- receptor. The results are consistent with the view that α5 receptors may represent a viable target for discovery of cognitive enhancing agents.

In addition, we have new data showing that modulation of α5-Rs by PWZ-029 rescues Hip-dependent memory in an AD rat model [PMID: 23634826] as evidenced by a significant decrease in the latency to reach the hidden platform (memory probe trials) on spatial water maze task (Figure 12). Roche has employed a similar strategy at α5 subtypes and recently has a drug in the clinic to treat symptoms of dementia in Down syndrome patients. It is well known many Down syndrome patients develop Alzheimer’s disease or a dementia with a very similar etiology. This is aimed at treating early onset Alzheimer’s patients.

4. PWZ-029 Docking within α5γ2 GABAA Receptor Subunit Homology Model

These studies with PWZ-029 led to the molecular model rendering of the compound docked within the α5γ2 BzR subtype (Figures 1316). The model figures have the following features:

The docking of PWZ-029 within the /BzR shows the molecule bound and interacting with specific amino acids. The A and B rings of the benzodiazepine framework undergo a -stacking interaction with HIS 105, indicated by the magenta coloring. At the other end of the molecule the methoxy lone pair and imidazole nitrogen lone pair act as a hydrogen bond acceptors with THR 210 and TYR 213, respectively. These interactions are shown by the aqua-blue descriptors.

5. Subtype Selective Agonists for α5 GABAA/Bz Receptors

Möhler has proposed that α5 selective inverse agonists or α5 selective agonists might enhance cognition [5, 13, 1618, 86]. This is because of the extrasynaptic pyramidal nature of α5β3γ2 subtypes, located almost exclusively in the hippocampus. Because of this, a new “potential agonist” which binds solely to α5β3γ2 subtypes was designed by computer modeling (see Figure 17). This ligand (DM-I-81, 9) has an agonist framework and binds only to α5β3γ2 subtypes [13, 17, 18, 86]. The binding potency at α5 subtypes is 176 nM. Although the 8-pendant phenyl of DM-I-81 was lipophilic and bound to the pocket, additional work on the 8-position of this scaffold has been abandoned and generally left as an acetylene or halide function, with a few exceptions. The steric bulk of the 8-phenyl moiety was felt detrimental to activity and potency which may have led to the weak binding affinity.

6. Alpha 5 Positive Allosteric Modulators in Schizophrenia

In addition to inverse agonists, a number of other α5-R positive allosteric modulators (PAMs) have been synthesized. These compounds, such as SH-053-2′F-R-CH3 (2), have been shown to decrease the firing rate of synapses controlling cognition and can be used to treat schizophrenia.

The following is reported by Gill, Cook, and Grace et al. [2738].

There are a number of novel benzodiazepine-positive allosteric modulators (PAMs), selective for the α5 subunit of the receptor, including SH-053-2′F-R-CH3 (2), which has been tested for its ability to effect the output of the HPC (hippocampal) in methylazoxymethanol- (MAM-) treated animals, which can lead to hyperactivity in the dopamine system [2738]. In addition, the effect of this compounds (2) response to amphetamine in MAM-animals on the hyperactive locomotor activity was examined. Schizophrenic-like symptoms can be induced into rats when treated prenatally with DNA-methylating agent, methylazoxymethanol, on gestational day (GD) 17. These neurochemical outcomes and changes in behavior mimic those found in schizophrenic patients. Systemic treatment with (2) resulted in a reduced number of spontaneously active DA (dopamine) neurons in the VTA (ventral tegmental area) of MAM animals (Figure 18) to levels seen in animals treated with vehicle (i.e., saline). To confirm the location of action, 2 was also directly infused into the ventral HPC (Figure 19) and was shown to have the same effect. Moreover, HPC neurons in both SAL and MAM animals showed diminished cortical-evoked responses following α5-R PAM treatment. This study is important for it supports a treatment of schizophrenia that targets abnormal HPC output, which in turn normalized dopaminergic neuronal activity [2738]. This is a novel approach to treat schizophrenia.

The pathophysiology of schizophrenia has identified hippocampal (HPC) dysfunction as a major mediator as reported by many including Anthony Grace [2738]. This included morphological changes, reduced HPC volume, and GAD67 expression [27, 28] that have been reported after death in the brains of patients with schizophrenia. Both HPC activation and morphology changes have been identified that can precede psychotic symptoms or correlate with severity of cognitive deficits [2933]. This has been shown in a cognitive test during baseline and activation.

Many animal models of schizophrenia were essential to behavioral pathology and have delivered new knowledge about the network disturbances that contribute to CNS disorder. This study shows that the offspring of MAM-treated animals showed both structural and behavioral abnormalities. These were consistent with those observed in patients with schizophrenia. The animals had reduced limbic cortical and HPC volumes with increased cell packing density and showed increased sensitivity to psychostimulants [3436]. In addition, the startle response in prepulse inhibition was reduced in MAM-treated animals and deficits in latent inhibition were observed [35]. Furthermore, a pathological rise in spontaneous dopamine (DA) activity by the ventral tegmental area (VTA) was observed that can be attributed to aberrant activation within the ventral HPC [36]. It was suggested that reductions in parvalbumin- (PV-) stained interneurons might be the reason for the hyperactivation of the HPC and disruption of normal oscillatory activity in the HPC and cortex of MAM animals [38, 61]. At least this is the prevailing hypothesis at the moment put forth by many investigators (see references cited in [2738]).

Selective α5-R positive allosteric modulator (2) was successful in reversing the pathological increase in tonic DA transmission in methylazoxymethanol rats by targeting abnormal hippocampal activity. In addition, the α5-PAM was able to reduce the behavioral sensitivity to psychostimulants observed in MAM rats (Figures 20 and 21). This suggests that novel α5-partial allosteric modulators should be effective in alleviating dopamine-mediated psychosis. However, if this drug can also restore rhythmicity within HPC-efferent structure, it may also affect other aspects of this disease state such as cognitive disabilities and negative symptoms. This study, using the MAM-model to induce symptoms of schizophrenia, shows that the use of α5-R targeting compounds could be an effective treatment in schizophrenic patients. The selective targeting solely of α5β3γ2 subunits, as opposed to unselective BZDs such as diazepam, could provide relief from the psychotic symptoms without producing adverse effects such as sedation [2738].

As reported by Gill, Grace et al. [36, 38, 4761].

Often initial antipsychotic drug treatments (APD) for schizophrenia are ineffective, requiring a brief washout period prior to secondary treatment. The impact of withdrawal from initial APD on the dopamine (DA) system is unknown. Furthermore, an identical response to APD therapy between normal and pathological systems should not be assumed. In another study by Gill, Grace et al., α5 positive allosteric modulator SH-053-2′F-R-CH3 (2) was used in the MAM neurodevelopmental model of schizophrenia which was used to study impact of withdrawal from repeated haloperidol (HAL) on the dopamine system [36, 38, 4761].

The following studies were designed to provide insight as to why a new drug to treat schizophrenia may be effective in Phase II clinical trials but fail in Phase III because of the large number of patients required for the study. Many of these patients in Phase III studies have altered neuronal pathways in the CNS because of long-term treatment with antipsychotics (sometimes 10–20 years) [36, 38, 4761].

Importantly, spontaneous dopamine activity reduction was observed in saline rats withdrawn from haloperidol with an enhanced locomotor response to amphetamine, indicating the development of dopamine supersensitivity. In addition, PAM treatment, as well as ventral HPC inactivation, removed the depolarization block of DA neurons in withdrawn HAL treated SAL rats. In contrast, methylazoxymethanol rats withdrawn from HAL displayed a reduction in spontaneous dopamine activity and enhanced locomotor response that was unresponsive to PAM treatment with SH-053-2′F-R-CH3 or ventral HPC inactivation [36, 38, 4761].

Prior HAL treatment withdrawal can restrict the efficacy of subsequent pharmacotherapy in the MAM model of schizophrenia. This is an extremely important result indicating that testing a new drug for schizophrenia in humans treated for years with both typical and atypical antipsychotics may result in a false negative with regard to treatment. Studies that support this hypothesis follow here [36, 38, 4761].

Novel therapeutics for the treatment of schizophrenia that exhibit initial promise in preclinical trials often fail to demonstrate sufficient efficacy in subsequent clinical trials. In addition, relapse or noncompliance from initial treatments is common, necessitating secondary antipsychotic intervention [47, 48]. Studies have shown that between 49 and 74% of schizophrenia patients discontinue the use of antipsychotic drug (APD) treatments within 18 months due to adverse side-effects [48, 49]. Current pharmacotherapies for schizophrenia target the pathological increase in dopamine system activity, as mentioned above. Common clinical practice for secondary antipsychotic application involves a brief withdrawal period from the initial APD. Unfortunately, the success of even secondary treatments is far from being optimal with the rehospitalization of patients being a common occurrence. The impact of repeated antipsychotic treatment and subsequent withdrawal on the dopamine system has not been adequately assessed [36, 38, 4761].

As indicated above, schizophrenia is a complex chronic psychiatric illness characterized by frequent relapses despite ongoing treatment. The search for more effective pharmacotherapies for the treatment of schizophrenia continues unabated. It is not uncommon for novel pharmaceuticals to demonstrate promise in preclinical trials but fail to show an adequate response in subsequent clinical trials. Indeed, evaluating the benefits of one APD versus another is complicated by clinical trials beset with high attrition rates and poor efficacy in satisfactorily reducing rehospitalization [47, 4952].

Previous work from the Gill, Grace et al.’s laboratory [36, 38, 4761] with the MAM model of schizophrenia has identified a potential novel therapeutic, a α5GABAAR PAM. The dopamine system pathology in the MAM model is likely the result of excessive output from the ventral HPC [36]. The α5GABAAR PAM was identified as a potential therapeutic due to the relatively selective expression of α5GABAAR in the ventral HPC and its potential for reducing HPC activity [5360]. When either administered systemically or directly infused into the ventral HPC, the α5GABAAR PAM (SH-053-2′F-R-CH3) was effective in reducing the dopamine system activation in MAM rats [38]. Anthony Grace, Gill et al. showed α5GABAAR PAM treatment was also effective in reducing the enhanced behavioral response to amphetamine in MAM rats, as stated above. Data from the present study sought to delineate whether the α5GABAAR PAM (SH-053-2′F-R-CH3) would remain effective in MAM rats withdrawn from prior neuroleptic treatment, a common occurrence in the patient population. In both SAL and MAM rats, there was a reduction in the spontaneous activity of dopamine neurons in the VTA after 7 days withdrawal from repeated HAL treatment. However, MAM rats continued to exhibit a greater activation of the dopamine system in comparison to SAL rats. Treatment with the α5GABAAR PAM was no longer effective in reducing the activity of dopamine neurons in the VTA in withdrawn HAL treated MAM rats. In contrast, α5GABAAR PAM treatment in the withdrawn HAL treated SAL rats instead increased the spontaneous activity of dopamine in the VTA (Figures 2225) [36, 38, 4761].

Similar to the effects seen following α5GABAAR PAM treatment, ventral HPC inactivation in withdrawn HAL treated SAL rats restored normal dopamine system activity by increasing the number of spontaneously active dopamine neurons. The disparate effect of withdrawal from HAL on the dopamine system between SAL and MAM rats provides a vital clue for the inconsistencies between preclinical trials for novel therapeutics that utilize normal subjects and subsequent clinical trials in a patient population [36, 38, 4761].

The data suggests underlying dopamine system pathology alters the impact of withdrawal from prior repeated HAL in the MAM model of schizophrenia. In addition, subsequent novel APD treatment loses efficacy following withdrawal from repeated HAL in MAM animals. This certainly has relevance to Phase III clinical trials of new drugs to treat schizophrenia [36, 38, 4761].

7. GABAA  α5 Positive Allosteric Modulators Relax Airway Smooth Muscle

Emala, Gallos, et al. [6675] have found that novel α5-subtype selective positive allosteric modulators relax airway smooth muscle from rodents and humans. The clinical need for new classes of bronchodilators for the treatment of bronchoconstrictive diseases such as asthma remains a major medical issue. Few novel therapeutics have been approved for targeting airway smooth muscle (ASM) relaxation or lung inflammation in the last 40 years [66]. In fact, several asthma-related deaths are attributed, in part, to long-acting β-agonists (LABA) [67]. Adherence to inhaled corticosteroids, the first line of treatment for airway inflammation in asthma, is very poor [68, 69]. Therapies that break our dependence on β-agonism for ASM relaxation would be a novel and substantial advancement.

These ASM studies were undertaken due to a pressing clinical need for novel bronchodilators in the treatment of asthma and other bronchoconstrictive diseases such as COPA. There are only three drug classes currently in clinical use as acute bronchodilators in the United States (methylxanthines, anticholinergics, and β-adrenoceptor agonists) [70]. Thus, a novel therapeutic approach that would employ cellular signaling pathways distinct from those used by these existing therapies involves modulating airway smooth muscle (ASM) chloride conductance via receptors to achieve relaxation of precontracted ASM [71, 72]. However, widespread activation of all receptors may lead to undesirable side effects (sedation, hypnosis, mucus formation, etc.). Thus, a strategy that selectively targets a subset of channels, those containing α subunits found to be expressed in airway smooth muscle, may be a first step in limiting side effects. Since human airway smooth muscle contains only α4 or α5 subunits [72], ligands with selectivity for these subunits are an attractive therapeutic option. Concern regarding nonselective receptor activation is not limited to the airway or other peripheral tissues. receptor ligands are classically known for their central nervous system effects of anxiolysis, sedation, hypnosis, amnesia, anticonvulsion, and muscle relaxant effects. Such indiscriminate activation of receptors in the CNS is exemplified by the side effects of classical benzodiazepines (such as diazepam) which were the underpinning for the motivation of a search for benzodiazepine (BZD) ligands that discriminate among the subunits of receptors [7375].

A novel approach to identify novel benzodiazepine derivatives to selectively target channels containing specific subunits was developed by Cook et al. in the 1980s that employed a pharmacophore receptor model based on the binding affinity of rigid ligands to BDZ/ receptor sites (as reviewed in 2007 [23]). From this series of receptor models for β3γ2 subtypes a robust model for α5 subtype selective ligands emerged, the result of which included the synthesis of a novel α5β3γ2 partial agonist modulator, SH-053-2′F-R-CH3 (2). The discovery of this and related ligands selective for α5 BDZ/-ergic receptors and the realization that only α4 and α5 subunits are expressed in channels on human airway smooth muscle yielded an ideal opportunity for targeting these α5-subunit containing channels for bronchorelaxation [6675].

The α5 subunit protein was first localized to the ASM layer of human trachea while costaining for the smooth muscle specific protein α actin (Figure 26). The first panel of Figure 26 shows   α5 protein stained with fluorescent green and blue fluorescent nuclear staining (DAPI). The second panel is the same human tracheal smooth muscle section simultaneously stained with a protein specific for smooth muscle, α actin, and the third panel is a merge of the first two panels showing costaining of smooth muscle with   α5 and α actin proteins. The fourth panel is a control omitting primary antibodies but including nuclear DAPI staining [6675].

After demonstrating the protein expression of receptors containing the α5 subunit, functional studies of isolated airway smooth muscle were performed in tracheal airway smooth muscle from two species. Human airway smooth muscle suspended in an organ bath was precontracted with a concentration of acetylcholine that was the EC50 concentration of acetylcholine for each individual airway smooth muscle preparation. The induced contraction was then relaxed with a β-agonist (isoproterenol) in the absence or presence of the   α5 ligand SH-053-2′F-R-CH3 (2). Figure 27(a) shows that the amount of relaxation induced by 10 nM isoproterenol was significantly increased if 50 μM SH-053-2′F-R-CH3 (2) was also present in the buffer superfusing the airway smooth muscle strip. Studies were also performed in airway smooth muscle from another species, guinea pig, that measured direct relaxation of a different contractile agonist, substance P. As shown in Figure 27(b), the amount of remaining contractile force 30 minutes after a substance P-induced contraction was significantly reduced in airway smooth muscle tracheal rings treated with SH-053-2′F-R-CH3 (2) [6675].

Following these studies in intact airway smooth muscle, cell based studies were initiated in cultured human airway smooth muscle cells to directly measure plasma membrane chloride currents and the effects of these currents on intracellular calcium concentrations. SH-053-2′F-R-CH3 (2) induced a Cl current in vitro using conventional whole cell patch clamp techniques [6675]. These electrophysiology studies were then followed by studies to determine the effect of these plasma membrane chloride currents on intracellular calcium concentrations following treatment of human airway smooth muscle cells with a ligand whose receptor couples through a Gq protein pathway, a classic signaling pathway that mediates airway smooth muscle contraction.

SH-053-2′F-R-CH3 (2) attenuated an increase in intracellular calcium concentrations induced by a classic Gq-coupled ligand, bradykinin (Figure 28(a)) [6675]. The attenuation by SH-053-2′F-R-CH3 (2) was significantly blocked by the antagonist gabazine (Figure 28(b)) indicating that SH-053-2′F-R-CH3 (2) was modulating receptors for these effects on cellular calcium [6675].

The major findings of these studies are that human airway smooth muscle expresses 5 subunit containing receptors that can be pharmacologically targeted by a selective agonist. The   α5 subunit selective ligand SH-053-2′F-R-CH3 (2) relaxed intact guinea pig airway smooth muscle contracted with substance P and augmented -agonist-mediated relaxation of intact human airway smooth muscle. The mechanism for these effects was likely mediated by plasma membrane chloride currents that contributed to an attenuation of contractile-mediated increases in intracellular calcium, a critical event in the initiation and maintenance of airway smooth muscle contraction [6675].

8. Recent Discovery of Alpha 5 Included Volume Differences: L4 Pocket as Compared to Other Bz/GABAergic Subtypes

The findings in both the MAM-model of schizophrenia and the relaxation of airway smooth muscle have led to the study of SH-053-2′F-R-CH3 and related compounds bound within the α5-/BzR (Figure 29). The SH-053-R-CH3 (15) and SH-053-S-CH3 (16) isomers have been previously described [23]. These compounds along with SH-053-2′F-R-CH3 and SH-053-2′F-S-CH3 have been tested for binding affinity and show selectivity for the 5-subunit (Table 3).


Compoundα1α2α3α4α5α6

SH-053-R-CH3, (15)202623771183>5000949.1>5000
SH-053-S-CH3, (16)166612631249>5000206.4>5000
SH-053-2′F-R-CH3, (2)759.1948.2768.8>500095.17>5000
SH-053-2′F-S-CH3, (17)3501411237>500019.2>5000

Data shown here are the means of two determinations which differed by less than 10%.

From examination of Figure 30 and Tables 3 and 4, it is clear the (R)-isomers bound to the α5 subtype while the (S)-isomers were selective for α2/α3/α5 subtypes.


Compoundα1α2α3α5

SH-053-2′F-R-CH3 (2)111/154124/185125/220183/387
SH-053-2′F-S-CH3 (17)116/164170/348138/301218/389

Efficacy at αβ3γ2 receptor subtypes as % of control current at 100 nM and 1 μM concentrations. Data presented as percent over baseline (100) at concentrations of 100 nM/1 μM.

From this data, these compounds were then used in examining the α5-binding pocket, most specifically the fluoroseries. In regard to molecular modeling, depicted in Figure 30 is the included volume and ligand occupation of the SH-053-2′F-S-CH3 (17) and SH-053-2′F-R-CH3 (2) enantiomers in the α5 subtype as well as the α2 subtype. It is clear a new pocket () has been located in the α5 subtype permitting 2 as well as 17 to bind to the α5 subtype. Examination of both ligands in the α2 subtype clearly illustrates the analogous region in the α2 subtype is not present and thus does not accommodate 2 for the pendant phenyl which lies outside the included volume in the space allocated for the receptor protein itself [23].

9. BzR GABA(A) Subtypes

In terms of potency, examination of the values in Table 4 [87], it is clear the R-isomer (2) shows more selectivity towards the α5-subunit, while the S-isomer (17) is potent at the α2/3/5 subunits. It is important, as postulated earlier [23], that the major difference in GABA(A)/Bz receptors subtypes stems from differences in asymmetry in the lipophilic pockets , , , , and in the pharmacophore/receptor model and indicates even better functional selectivity is possible with asymmetric BzR ligands.

The synthetic switching of chirality at the C-4 position of imidazobenzodiazepines to induce subtype selectivity was successful. Moreover, increase of the potency of imidazobenzodiazepines can be achieved by substitution of the 2′-position hydrogen atom with an electron rich atom (fluorine) on the pendant phenyl ring in agreement with Haefely et al. [88], Fryer [89, 90], and our own work [22, 91]. The biological data on the two enantiomeric pairs of benzodiazepine ligands confirm the ataxic activity of BZ site agonists is mediated by α1β2/3γ2 subtypes, as reported in [23, 9193]. The antianxiety activity in primates of the S isomers was preserved with no sedation. In only one study in rodents was any sedation observed; the confounding sedation was observed in both the S isomer (functionally selective for α2, α3, and α5 receptor subtypes) and R isomer (essentially selective for α5 subtype) and may involve at least, in part, agonist activity at α5 BzR subtypes. There are some α5 BzR located in the spinal cord which might be the source of the decrease in locomotion with SH-053-2′F-R-CH3 and SH-053-2′F-S-CH3; however, this is possibly some type of stereotypical behavior. Hence in agreement with many laboratories including our own [23, 92, 93] the best potential nonsedative, nonamnesic, antianxiety agents stem from ligands with agonist efficacy at α2 subtypes essentially silent at α1 and α5 subtypes (to avoid sedation) [91]. It must be pointed out again; however, in primates Fischer et al. [87] observed a potent anxiolytic effect with no sedation with the 2′F-S-CH3 (17) isomer, while the 2′F-R-CH3 (2) isomer exhibited only a very weak anxiolytic effect.

Numerous groups have done modeling and SAR studies on different classes of compounds which have resulted in a few different pharmacophore models based on the benzodiazepine binding site (BS) of the receptor [94]. These models are employed to gain insight in the interactions between the BS and the ligand. These have been put forth by Loew [7, 95, 96], Crippen [97, 98], Codding [76, 77, 99101], Fryer [89, 90, 94], Gilli and Borea [102105], Tebib et al. [106], and Gardner [107], as well as from Professors Sieghart, Cromer, and our own laboratory [21, 39, 40, 76, 7882, 108118].

The Milwaukee-based pharmacophore/receptor model is a comprehensive building of the BzR using radioligand binding data and receptor mapping techniques based on 12 classes of compounds [20, 23, 39, 40, 42, 111, 119122]. This model (Figure 31) [79] has brought together previous models which have used data from the activity of antagonists, positive allosteric modulators, and negative allosteric modulators and included the new models for the “diazepam-insensitive” (DI) sites [123]. Four basic anchor points, , , , and , were assigned, and 4 additional lipophilic regions were defined as , , , and the new (see captions in Figure 31 for details); regions , , and represent negative areas of steric repulsion. As previously reported, the synthesis of both partial agonists and partial inverse agonists has been achieved by using parts of this model [99, 100, 104, 105, 119, 124127].

The cloning, expression, and anatomical localization of multiple GABA(A) subunits have facilitated both the identification and design of subtype selective ligands. With the availability of binding data from different recombinant receptor subtypes, affinities of ligands from many different structural classes of compounds have been evaluated.

Illustrated in Figure 31 is the [3,4-c]quinolin-3-one CGS-9896 (18) (dotted line), a diazadiindole (19) (thin line), and diazepam (20) (thick line) fitted initially to the inclusive pharmacophore model for the BzR. Sites (Y210) and (H102) represent hydrogen bond donor sites on the receptor protein complex while (T142) represents a hydrogen bond acceptor site necessary for potent inverse activity in vivo. , , , , and are four lipophilic regions in the binding pharmacophore. Descriptors , , and are regions of negative steric repulsion.

Based on SAR data obtained for these ligands at 6 recombinant BzR subtypes [128132], an effort has been undertaken to establish different pharmacophore/receptor models for BzR subtypes. The alignment of the twelve different structural classes of benzodiazepine receptor ligands was earlier based on the least squares fitting of at least three points. The coordinates of the four anchor points (, , , and ) employed in the alignment are outlined in Figure 32. Herein are described the results from ligand-mapping experiments at recombinant BzR subtypes of 1,4-benzodiazepines, imidazobenzodiazepines, β-carbolines, diindoles, pyrazoloquinolinones, and others [126]. Some of the differences and similarities among these subtypes can be gleaned from this study and serve as a guide for future drug design.

10. α1 Updates

10.1. Beta-Carbolines

A series of 3,6-disubstituted β-carbolines was prepared and evaluated for their in vitro affinity at αxβ3γ2 GABA(A)/BzRr subtypes by radioligand binding assays in search of α1β3γ2 subtype selective compounds (Figure 33). A potential therapeutic application of such antagonist analogs is to treat alcohol abuse [133, 134]. Analogues of βCCt (21) were synthesized via a carbonyldiimidazole-mediated method by Yin et al. [85] and the related 6-substituted β-carboline-3-carboxylates including WYS8 (27) were synthesized from 6-iodo βCCt (29). Bivalent ligands (42 and 43) were also synthesized to increase the scope of the structure-activity relationships (SAR) to larger ligands. An initial SAR on the first analogs demonstrated that compounds with larger side-groups at C6 were well tolerated as they projected into the domain (see 42 and 43) [85]. Moreover, substituents located at C3 exhibited a conserved stereo interaction in lipophilic pocket , while N2 likely participated in hydrogen bonding with . Three novel β-carboline ligands (21, 23, and 27) permitted a comparison of the pharmacological properties with a range of classical benzodiazepine receptor antagonists (flumazenil, ZK93426) from several structural groups and indicated these β-carbolines were “near GABA neutral antagonists.” Based on the SAR, the most potent (in vitro) α1 selective ligand was the 6-substituted acetylenyl βCCt (WYS8, 27). In a previous study both 21 and 23 were able to reduce the rate at which rats self-administrated alcohol in alcohol preferring and HAD rats but had little or no effect on sucrose self-administration [85]. 3-PBC (23) was also active in baboons [134]. This data has been used in updating the pharmacophore model in the α1-subtype.

11. The Updated Included Volume Models

Illustrated in Figure 34 is the included volume of the updated pharmacophore receptor model of the α1β3γ2 subtype of Clayton [22]. The current model for the α1β3γ2 subtype has several new features. The cyclopropyl group of CD-214 extended 2 Å past the descriptor slightly increasing its volume. The trimethylsilyl group of QH-II-82 and WYS7 illustrates how well bulky groups are tolerated near the entrance of the binding pocket. Despite not being as potent, dimers of beta carbolines, WYS2 and WYS6, bound to α1 subtypes at 30 nM and 120 nM, respectively. Their ability to bind, albeit weakly, supports the location of the binding site entrance from the extracellular domain. The included volume of the α1β3γ2 subtype was previously 1085.7 cubic angstroms. The volume has now been measured as 1219.2 cubic angstroms. Volume measurements should be used carefully as the binding site is not enclosed and the theoretical opening near is not clearly demarcated. Dimers were excluded from the included volume exercise because although they bound to the receptor, they represented compounds which were felt to extend outside the receptor binding pocket when docked to the protein. Where appropriate, their monomers were included in the included volume analysis. Ligands considered for the included volume in Table 5 exhibited potent binding at α1 subtypes ( ≤ 20 nM) but were not necessarily subtype selective. The binding data for ligands at -subtypes follow (Tables 610; structures located in Clayton [22] and Supporting Information, Appendix III in Supplementary Material available online at http://dx.doi.org/10.1155/2015/430248).


Cook code

WY-TSC-4 (WYS8)0.0070.991.6351.04
SH-TSC-2 (BCCT)0.030.04190.03569.32
QH-II-090 (CGS-8216)0.050.080.120.2517
XLI-2860.0510.0640.1180.684
QH-II-0770.060.080.050.124
QH-II-0920.070.030.04ND0.17ND
JYI-570.0760.0760.131ND0.036ND
QH-II-0850.080.060.02ND0.08ND
XHE-II-0240.090.180.32140.2411
PWZ-007A0.110.10.09ND0.210
CGS82160.13NDNDNDND46
SPH-1210.141.191.72ND4479
QH-II-0750.180.210.25ND1.340
PZII-0280.2ND0.2ND0.321.9
CGS98950.21NDNDNDND9.3
PWZ-00710.230.170.12ND0.4417.31
XHE-III-240.25ND822210328
JYI-420.2570.1460.278ND0.256ND
CGS98960.28NDNDNDND181
JYI-64 (C17H12N4FBr)0.3051.1110.62ND0.875000
PZII-0290.34ND0.79ND0.5210
BRETAZENIL0.350.640.2ND0.512.7
FG82050.42.081.16ND1.54227
YT-50.4210.603436.06ND1.695ND
6-PBC0.491.212.2 ND2.391343
QH-1460.49ND0.76ND7.710000
DM-II-90 (C17H12N4BrCl)0.50510.63ND0.375000
SPH-1650.632.794.85ND10.41150
BCCt0.721518.9ND110.85000
SH-I-048A0.7740.17230.383ND0.11ND
alprazolam0.80.591.43ND1.5410000
Ro15-17880.80.91.05ND0.6148
WYS10 C14H9F3N2O20.883625.6ND548.715.3
WY-B-150.920.830.5820804.42646
WY-A-99-2 (WYS8)0.97211110220002081980
XHE-III-06a12151.837
Xli366 C22H21N3O21NDNDNDNDND
JYI-59 (C22H13N3O2F4)1.082.611.82ND11.55000
WYSC1 C16H16N2O21.0945.4412.3ND69.821.2
MLT-I-701.11.21.1ND40.31000
SVO-8-301.15.35.32.80.615
BCCE1.24.95.7ND26.82700
XHE-III-041.221.12190.4500
XLi350 C17H11ClN2O1.2241.188NDND2.9ND
XHE-III-491.35.54.238.711.385.1
PWZ-009A11.341.311.26ND0.842.03
DM-2391.5ND0.53ND0.146.89
XLi351 C21H21ClN2OSi1.5070.967NDND1.985ND
XLi352 C18H13ClN2O1.560.991NDND1.957ND
TG-4-391.634245.61.423
TG-II-821.62.92.8 ND11000
CM-A871.624.5414.7310004.611000
QH-II-0821.71.81.6ND6.1100
JYI-49 (C20H12N3O2F4Br)1.872.38NDND6.73390
LJD-III-15E1.931419ND70.81000
SPH-3825.410.8ND18.53000
XHE-I-09327.18.91107201162
MSA-IV-352.11621ND9953000
JYI-19 (C23H23N3O3S)2.176205NDND3412.7
FLUNITRAZEPAM2.22.54.5ND2.12000
YCT-52.211.4616.3 ND20010000
TJH-IV-512.3917.414.5ND31610000
WYS13 C20H18N2O32.4421327.5ND1635000
YT-III-252.5315.7865.691ND0.095ND
XHE-III-142.6101327
WYS9 C16H15IN2O22.7222.223.1ND562122
JYI-472.7592.2820.511ND0.427ND
CM-A82a2.788.9324.5110007.491000
TG-4-292.83.92.72.10.183.9
XLi268 C17H13BrN42.81450.6862NDND0.6243ND
JYI-54 (C24H15N3O3F4)2.891726.7ND571890
MMB-II-74324.541.7500125.71000
MMB-III-01631.97210740.26211
MMB-III-1631.97210740.26211
QH-II-080b33.74.7ND241000
YCT-7A323.830.5ND24010000
JYI-32 (C20H15N3O2BrF)3.074.96NDND2.9252.24
Ro15-45133.32.62.5ND0.263.8
XHE-II-0173.310725817294
XLi-JY-DMH ANX33.30.581.9ND4.45000
MLT-II-183.411.711ND22510000
TJH-V-883.4130 ND140.910000
XLI-2TC3.4421.67344.08ND1.121
WYS15 C22H20N2O23.632.0244.3ND76.55000
CM-A573.72740ND2541000
XHE-II-006b3.7151218971441000
JYI-60 3.731.6354.3ND1.75000
RY-0083.757.24.14ND1.1144.3
MLT-II-183.912.224.4ND21010000
OMB-183.91.23.417330.85
WY-B-09-13.9983210004612000
SHU-1-194127481484
ZK 934234.14.26ND4.51000
WY-B-23-2 (WYS11)4.237.739200017669.4
WY-B-23-2 (WYS11)4.237.773 ND17669.4
WY-B-99-14.44.55.582000472000
WY-B-26-24.4544.5742.6620001242000
XHE-II-006a4.74.4201876893531
CM-B014.8313410002861000
PWZ-0854.86138.5ND0.5540
MLT-II-165.0510.4118.4ND26010000
3 PBC5.352.368.8ND5911000
MA-3-PROPOXYL5.352.368.8ND5911000
TJH-IV-435.4230.1948.9ND47510000
DMCM5.698.294ND1.04134
DM-1395.8ND169ND9.25325
XHE-II-073A (R ENRICHED)5.91110151.18140
MSR-I-0326.218.74ND3.374.9
JYI-70 (C19H13N4F)6.32.1NDND0.565000
XLi343 C20H19ClN2OSi6.37517.71NDND150.5ND
3 EBC6.4325.128.2ND8261000
DM-1466.44ND148 ND4.23247
DM-2156.74ND7.42 ND0.2938.28
ZG69A6.816.39.2ND0.8554.6
ZG-69a (Ro15-1310)6.816.39.2ND0.8554.6
WY-B-14 (WYS7)6.84303620001081000
YT-II6.9320.87123.518ND5.119ND
SVO-8-6774126152.3191
MLT-II-347.0415.9522.3ND1581000
SPH-1957.2168.5283.5ND27110000
XHE-I-0657.2171850057500
ZG-2347.2522.149.84ND0.35.25
SH-I-047.36.1365.1 ND7.664ND
XHE-I-0387.3534ND1321000
XHE-III-137.3 ND7.18801.6311
WY-B-257.6406620002632000
CM-A49 (R)7.732.543ND691000
SVO-8-1482586.90.914
TG-4-298.310.26.9ND0.47.61
XHE-II-0028.318133.91.511
WY-B-14 (WYS7)8.5165245 ND17865000
XHE-II-011960393233901000
WY-B-27-29.191117220004492000
QH-II-0639.49.331ND7.73000
JC184 C13H9BrN2OS9.60610.5NDND6.709ND
ZG-2089.711.210.9ND0.384.6
RY-I-31104519ND61000
WY-B-23-110334310001892000
RY-09810.122.216.5ND1.68100
Hz148 C18H15N310.985000NDND2565000
SVO-8-20114028198.6138
XHE-II-073B (S-ENRICHED)111712332.1269
SH-I-08511.084.86613.75ND0.24ND
PWZ-09611.13616.9ND1.0751.5
ZG-16811.210.79.2ND0.479.4
CM-A7711.5151.9105.16100042.621000
WY-B-2012394720001223000
ABECARNIL12.415.37.5ND61000
SH-I-89S12.788.5628.145ND3.23ND
ZG-21312.849.830.2ND3.522.5
EDC-I-07112.983.1NDND3145000
MMB-III-1413136.93331.1333
DM-17313.1ND38.1ND0.78118
XLI-34813.5611.171.578ND82.05ND
EDC-I-09313.6423NDND29125000
diazepam142015ND11ND
XLi223 C22H20BrN3O2148.7181000102000
WYSC2 C15H11F3N2O214.14113170ND51861.2
SH-I-03014.4211.0419.09ND1.89ND
CM-A10014.4944.91123.8100065.311000
RY-03314.85625.3ND1.7222.9
HJ-I-03715.078.12728.29ND0.818ND
YT-615.3187.860.49ND1.039ND
EDC-II-04415.4ND293ND3231000
CM-A5816120184ND10001012
QH-II-067a163152ND1993000
CD-21416.448.242.5ND9.8168
JYI-06 (C23H23N3O4)16.55.485000ND12.65000
CM-A50 (S)175988ND1441000
RY-06117136.7ND0.331
ZG-22417.133.750ND2.530.7
ZG-63A17.321.629.1ND0.654
DM-II-30 (C20H13N3O2BrF3)17.613.428.51ND7.85000
CM-A641860116ND2161000
RY-071195691ND7.2266
WZ-11319.213.213.4ND11.5300
YT-III-2319.8323.6519.87ND1.105ND
CM-E09b202219550.4569
MMB-II-9020245.790.2536

Affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell membranes expressing human receptors of compositions 132, 232, 332, 432, 532, and 632 [139]. Data represent the average of at least three determinations with a SEM of ±5%. The structures of these ligands are in the Ph.D. thesis of Clayton (2011) [22] and Supporting Information.

Cook code

QH-II-0920.070.030.04ND0.17ND
SH-TSC-2 (BCCT)0.030.04190.035ND69.32ND
QH-II-0850.080.060.02ND0.08ND
XLI-2860.0510.0640.118ND0.684ND
JYI-570.0760.0760.131ND0.036ND
QH-II-090 (CGS-8216)0.050.080.12ND0.2517
QH-II-0770.060.080.05ND0.124
PWZ-007A0.110.10.09ND0.210
JYI-420.2570.1460.278ND0.256ND
PWZ-00710.230.170.12ND0.4417.31
SH-I-048A0.7740.17230.383ND0.11ND
XHE-II-0240.090.180.32140.2411
QH-II-0750.180.210.25ND1.340
XLi-JY-DMH ANX33.30.581.9ND4.45000
alprazolam0.80.591.43ND1.5410000
YT-50.4210.603436.06ND1.695ND
BRETAZENIL0.350.640.2ND0.512.7
XLi268 C17H13BrN42.81450.6862NDND0.6243ND
WY-B-150.920.830.5820804.42646
YT-II6.9320.87123.518ND5.119
Ro15-17880.80.91.05ND0.6148
XLi351 C21H21ClN2OSi1.5070.967NDND1.985ND
WY-TSC-4 (WYS8)0.0070.991.63ND51.04ND
XLi352 C18H13ClN2O1.560.991NDND1.957ND
DM-II-90 (C17H12N4BrCl)0.50510.63ND0.375000
JYI-64 (C17H12N4FBr)0.3051.1110.62ND0.875000
XLi350 C17H11ClN2O1.2241.188NDND2.9ND
SPH-1210.141.191.72ND4479
MLT-I-701.11.21.1ND40.31000
OMB-183.91.23.417330.85
6-PBC0.491.212.2ND2.391343
YT-III-27132.541.262.35ND103ND
PWZ-009A11.341.311.26ND0.842.03
DM-II-72 (C15H10N20BrCl)50001.37NDND2.025000
JYI-60 (C17H11N2OF)3.731.6354.3ND1.75000
XLI-2TC3.4421.67344.08ND1.121ND
QH-II-0821.71.81.6ND6.1100
TC-YT-II-76101.11.8975.816ND11.99ND
MMB-III-01631.97210740.26211
MMB-III-1631.97210740.26211
XHE-III-06a12151.837
XHE-III-041.221.12190.4500
WYS15 C22H20N2O23.632.0244.3ND76.55000
FG82050.42.081.16ND1.54227
JYI-70 (C19H13N4F)6.32.1NDND0.565000
JYI-472.7592.2820.511ND0.427ND
JYI-49 (C20H12N3O2F4Br)1.872.38NDND6.73390
FLUNITRAZEPAM2.22.54.5ND2.12000
JYI-59 (C22H13N3O2F4)1.082.611.82ND11.55000
Ro15-45133.32.62.5ND0.263.8
SPH-1650.632.794.85ND10.41150
YT-II-7695.342.7970.056ND0.04ND
TG-II-821.62.92.8ND11000
QH-II-080b33.74.7ND241000
TG-4-292.83.92.72.10.183.9
PS-1-34B C20H17N4BrOND4.1983.928NDNDND
ZK 934234.14.26ND4.51000
XHE-II-006a4.74.4201876893531
WY-B-99-14.44.55.582000472000
CM-A871.624.5414.7310004.611000
OMB-19224.62033333.540
SH-I-08511.084.86613.75ND0.24ND
BCCE1.24.95.7ND26.82700
JYI-32 (C20H15N3O2BrF)3.074.96NDND2.9252.24
XHE-I-0387.3534ND1321000
SVO-8-301.15.35.32.80.615
SPH-3825.410.8ND18.53000
WYSC1 C16H16N2O21.0945.4412.3ND69.821.2
JYI-06 (C23H23N3O4)16.55.485000ND12.65000
XHE-III-491.35.54.238.711.385.1
YT-III-252.5315.7865.691ND0.095ND
SH-I-047.36.1365.1ND7.664ND
XHE-I-09327.18.91107201162
RY-0083.757.24.14ND1.1144.3
DMH-D-053 (C43H30N6O4)2367.42725000194.25000
WY-B-09-13.9983210004612000
HJ-I-03715.078.12728.29ND0.818ND
DMCM5.698.294ND1.04134
SH-I-89S12.788.5628.145ND3.23ND
XLi223 C22H20BrN3O2148.7181000102000
CM-A82a2.788.9324.5110007.491000
QH-II-0639.49.331ND7.73000
9.49.331ND7.73000
XHE-II-0173.310725817294
TG-4-298.310.26.9ND0.47.61
MLT-II-165.0510.4118.4ND26010000
JC184 C13H9BrN2OS9.60610.5NDND6.709ND
ZG-16811.210.79.2ND0.479.4
XHE-II-073A (R ENRICHED)5.91110151.18140
XLI-8TC21.5211.012.155ND4.059ND
SH-I-03014.4211.0419.09ND1.89ND
XLI-34813.5611.171.578ND82.05ND
ZG-2089.711.210.9ND0.384.6
YT-TC-3141.411.43118.1ND29.22ND
YCT-52.211.4616.3ND20010000
MLT-II-183.411.711ND22510000
XHE-II-O53-ACID50.3511.844ND5.95000
SHU-1-194127481484
RY-067211210ND0.3742
DM-III-01 (C18H12N3O2Br)500012NDND4.735000
MLT-II-183.912.224.4ND21010000
SH-053-2′F 21.9912.3434.9ND0.671ND
WYS13 C20H18N2O32.4421327.5ND1635000
PWZ-0854.86138.5ND0.5540
MMB-III-1413136.93331.1333
RY-06117136.7ND0.331
WZ-11319.213.213.4ND11.5300
YT-II-8332.7413.2224.1ND3.548ND
DM-II-30 (C20H13N3O2BrF3)17.613.428.51ND7.85000
LJD-III-15E1.931419ND70.81000
YT-III-272295.914.9810.77ND103.3ND
BCCt0.721518.9ND110.85000
XHE-II-006b3.7151218971441000
ABECARNIL12.415.37.5ND61000
MLT-II-347.0415.9522.3ND1581000
MSA-IV-352.11621ND9953000
JYI-04 (C21H23N3O3)28.316NDND0.511.57
PS-1-35 C23H22N5OBrND16.0324.41NDNDND
ZG69A6.816.39.2ND0.8554.6
ZG-69a (Ro15-1310)6.816.39.2ND0.8554.6
YT-III-42382.916.8344.04ND9.77ND
XHE-I-0657.2171850057500
XHE-II-073B (S-ENRICHED)111712332.1269
TJH-IV-512.3917.414.5ND31610000
SH-I-047171017.521222ND1519ND
XLi343 C20H19ClN2OSi6.37517.71NDND150.5ND
XHE-II-0028.318133.91.511
YT-III-38146118.2114.63ND3999
JYI-72 (C22H21N4SiF)48.518.5NDND11.55000
MSR-I-0326.218.74ND3.374.9
JC208 C15H10N2OS22.4218.89NDND5.039ND
diazepam142015ND11ND

Affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell membranes expressing human receptors of compositions 132, 232, 332, 432, 532, and 632 [22, 139]. Data represent the average of at least three determinations with a SEM of ±5%. ND: not determined.

Cook code

QH-II-0850.080.060.02ND0.08ND
SH-TSC-2 (BCCT)0.030.04190.035ND69.32ND
QH-II-0920.070.030.04ND0.17ND
QH-II-0770.060.080.05ND0.124
YT-II-7695.342.7970.056ND0.04ND
PWZ-007A0.110.10.09ND0.210
XLI-2860.0510.0640.118ND0.684ND
QH-II-090 (CGS-8216)0.050.080.12ND0.2517
PWZ-00710.230.170.12ND0.4417.31
JYI-570.0760.0760.131ND0.036ND
BRETAZENIL0.350.640.2ND0.512.7
PZII-0280.2ND0.2ND0.321.9
QH-II-0750.180.210.25ND1.340
JYI-420.2570.1460.278ND0.256ND
XHE-II-0240.090.180.32140.2411
SH-I-048A0.7740.17230.383ND0.11ND
JYI-5541.39ND0.504ND24.75ND
JYI-472.7592.2820.511ND0.427ND
DM-2391.5ND0.53ND0.146.89
WY-B-150.920.830.5820804.42646
JYI-64 (C17H12N4FBr)0.3051.1110.62ND0.875000
DM-II-90 (C17H12N4BrCl)0.50510.63ND0.375000
QH-1460.49ND0.76ND7.710000
PZII-0290.34ND0.79ND0.5210
WYS19 C26H32N2O4Si NDND0.89NDNDND
XHE-III-06a12151.837
Ro15-17880.80.91.05ND0.6148
MLT-I-701.11.21.1ND40.31000
XHE-III-041.221.12190.4500
FG82050.42.081.16ND1.54227
PWZ-009A11.341.311.26ND0.842.03
alprazolam0.80.591.43ND1.5410000
XLI-34813.5611.171.578ND82.05ND
QH-II-0821.71.81.6ND6.1100
WY-TSC-4 (WYS8)0.0070.991.63ND51.04ND
SPH-1210.141.191.72ND4479
XLi-JY-DMH ANX33.30.581.9ND4.45000
MMB-III-01631.97210740.26211
MMB-III-1631.97210740.26211
XLI-8TC21.5211.012.155ND4.059ND
6-PBC0.491.212.2ND2.391343
YT-III-27132.541.262.35ND103ND
Ro15-45133.32.62.5ND0.263.8
TG-4-292.83.92.72.10.183.9
TG-II-821.62.92.8 ND11000
OMB-183.91.23.417330.85
YT-II6.9320.87123.518ND5.119ND
PS-1-34B C20H17N4BrOND4.1983.928NDNDND
DMCM5.698.294ND1.04134
MSR-I-0326.218.74ND3.374.9
RY-0083.757.24.14ND1.1144.3
XHE-III-491.35.54.238.711.385.1
JYI-60 (C17H11N2OF)3.731.6354.3ND1.75000
FLUNITRAZEPAM2.22.54.5ND2.12000
XLI-31760.2424.054.562ND0.295ND
QH-II-080b33.74.7ND241000
SPH-1650.632.794.85ND10.41150
SH-I-047.36.1365.1ND7.664ND
SVO-8-301.15.35.32.80.615
WY-B-99-14.44.55.582000472000
YT-III-252.5315.7865.691ND0.095ND
BCCE1.24.95.7ND26.82700
MMB-II-9020245.790.2536
TC-YT-II-76101.11.8975.816ND11.99ND
ZK 934234.14.26ND4.51000
RY-06117136.7ND0.331
JYI-54 (C24H15N3O3F4)2.891726.7ND571890
TG-4-298.310.26.9ND0.47.61
MMB-III-1413136.93331.1333
XHE-II-0173.310725817294
SHU-1-194127481484
XHE-III-137.3ND7.18801.6311
DM-2156.74ND7.42ND0.2938.28
ABECARNIL12.415.37.5ND61000
SVO-8-1482586.90.914
XHE-III-240.25ND822210328
SH-I-89S12.788.5628.145ND3.23ND
PWZ-0854.86138.5ND0.5540
XHE-I-09327.18.91107201162
ZG-16811.210.79.2ND0.479.4
ZG69A6.816.39.2ND0.8554.6
ZG-69a (Ro15-1310)6.816.39.2ND0.8554.6
ZG-2347.2522.149.84ND0.35.25
XHE-II-073A (R ENRICHED)5.91110151.18140
RY-067211210ND0.3742
XHE-III-142.6ND101327
YT-III-272295.914.9810.77ND103.3ND
SPH-3825.410.8ND18.53000
ZG-2089.711.210.9ND0.384.6
MLT-II-183.411.711ND22510000
DM-II-33 (C20H13N3O2BrCl3)88.68511.6ND26.25000
JYI-59 (C22H13N3O2F4)1.082.611.82ND11.55000
XHE-II-006b3.7151218971441000
XHE-II-073B (S-ENRICHED)111712332.1269
CM-B44 (ss)3243123794.3485
WYSC1 C16H16N2O21.0945.4412.3ND69.821.2
JYI-4875.5990.6812.78ND31.28ND
XHE-II-0028.318133.91.511
RY-076262713ND0.722
WZ-11319.213.213.4ND11.5300
SH-I-08511.084.86613.75ND0.24ND
CM-E102326142150.5196
TJH-IV-512.3917.414.5ND31610000
YT-III-38146118.2114.63ND3999ND
CM-A871.624.5414.7310004.611000
diazepam142015ND11ND
RY-053492915ND146
YCT-52.211.4616.3ND20010000
RY-09810.122.216.5ND1.68100
PWZ-09611.13616.9ND1.0751.5
XLi223 C22H20BrN3O2148.7181000102000
XHE-I-0657.2171850057500
SH-I-02B29.82131518ND74.05ND
MLT-II-165.0510.4118.4ND26010000
RY-024 C19H19N3O326.926.318.7ND0.45.1
BCCt0.721518.9ND110.85000
LJD-III-15E1.931419ND70.81000
CM-E09b202219550.4569
RY-I-31104519ND61000
SH-I-03014.4211.0419.09ND1.89ND
YT-III-2319.8323.6519.87ND1.105ND
XHE-II-006a4.74.4201876893531
OMB-19224.62033333.540
XHE-III-06b32332029928.6740

Affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell membranes expressing human receptors of compositions 132, 232, 332, 432, 532, and 632 [22, 139]. Data represent the average of at least three determinations with a SEM of ±5%. ND: not determined.

Cook code

CM-D45 C19H21N3O490.565.530.30.151.650.23
CM-D4434.356.320.70.330.570.92
XHE-III-7477105380.422.25.8
TG-4-292.83.92.72.10.183.9
SVO-8-301.15.35.32.80.615
XHE-II-0028.318133.91.511
XHE-III-06a12151.837
RY-080 C17H15N3O328.421.425.85.30.4928.8
TG-4-391.634245.61.423
SVO-8-1482586.90.914
RY-023 C22H27N3O3Si197142.62557.82.6158.6
MMB-II-9020245.790.2536
XHE-III-142.6101327
XHE-II-0240.090.180.32140.2411
XHE-II-073A (R ENRICHED)5.91110151.18140
SVO-8-6774126152.3191
CM-B31i (ss)9018478184.9121
SVO-8-20114028198.6138

Affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell membranes expressing human receptors of compositions 132, 232, 332, 432, 532, and 632 [22, 139]. Data represent the average of at least three determinations with a SEM of ±5%. ND: not determined.

Cook code

JYI-570.0760.0760.131ND0.036ND
YT-II-7695.342.7970.056ND0.04ND
QH-II-0850.080.060.02ND0.08ND
YT-III-252.5315.7865.691ND0.095ND
SH-I-048A0.7740.17230.383ND0.11ND
QH-II-0770.060.080.05ND0.124
DM-2391.5ND0.53ND0.146.89
QH-II-0920.070.030.04ND0.17ND
TG-4-292.83.92.72.10.183.9
SH-I-751487989.9773ND0.1825ND
PWZ-007A0.110.10.09ND0.210
XHE-II-0240.090.180.32140.2411
SH-I-08511.084.86613.75ND0.24ND
MMB-II-9020245.790.2536
QH-II-090 (CGS-8216)0.050.080.12ND0.2517
JYI-420.2570.1460.278ND0.256ND
MMB-III-01631.97210740.26211
MMB-III-1631.97210740.26211
Ro15-45133.32.62.5ND0.263.8
DM-2156.74ND7.42ND0.2938.28
XLI-31760.2424.054.562ND0.295ND
RY-06117136.7ND0.331
ZG-2347.2522.149.84ND0.35.25
PZII-0280.2ND0.2ND0.321.9
RY-067211210ND0.3742
DM-II-90 (C17H12N4BrCl)0.50510.63ND0.375000
ZG-2089.711.210.9ND0.384.6
XHE-III-041.221.12190.4500
TG-4-298.310.26.9ND0.47.61
RY-024 C19H19N3O326.926.318.7ND0.45.1
JYI-472.7592.2820.511ND0.427ND
PWZ-00710.230.170.12ND0.4417.31
CM-E09b202219550.4569
ZG-16811.210.79.2ND0.479.4
RY-080 C17H15N3O328.421.425.85.30.4928.8
BRETAZENIL0.350.640.2ND0.512.7
CM-E102326142150.5196
JYI-04 (C21H23N3O3)28.316NDND0.511.57
PZII-0290.34ND0.79ND0.5210
PWZ-0854.86138.5ND0.5540
JYI-70 (C19H13N4F)6.32.1NDND0.565000
CM-D4434.356.320.70.330.570.92
SVO-8-301.15.35.32.80.615
Ro15-17880.80.91.05ND0.6148
XLi268 C17H13BrN42.81450.6862NDND0.6243ND
ZG-63A17.321.629.1ND0.654
SH-053-2′F 21.9912.3434.9ND0.671ND
XLI-2860.0510.0640.118ND0.684ND
SH-I-S6622.9330.3655.26ND0.69ND
RY-076262713ND0.722
DM-17313.1ND38.1ND0.78118
OMB-183.91.23.417330.85
HJ-I-03715.078.12728.29ND0.818ND
PWZ-009A11.341.311.26ND0.842.03
ZG69A6.816.39.2ND0.8554.6
ZG-69a (Ro15-1310)6.816.39.2ND0.8554.6
JYI-64 (C17H12N4FBr)0.3051.1110.62ND0.875000
SVO-8-1482586.90.914
JYI-03 (C21H21N3O3)185.4107NDND0.9543.34
TG-II-821.62.92.8ND11000
RY-053492915ND146
YT-615.3187.860.49ND1.039ND
DMCM5.698.294ND1.04134
PWZ-09611.13616.9ND1.0751.5
MMB-III-1413136.93331.1333
YT-III-2319.8323.6519.87ND1.105ND
RY-0083.757.24.14ND1.1144.3
XLI-2TC3.4421.67344.08ND1.121ND
XHE-II-073A (R ENRICHED)5.91110151.18140
QH-II-0750.180.210.25ND1.340
RY-054594427ND1.3126
TG-4-391.634245.61.423
XHE-II-0028.318133.91.511
RY-031 (RY-10)20.42726.1ND1.5176
FG82050.42.081.16ND1.54227
alprazolam0.80.591.43ND1.541000
XHE-III-137.3 ND7.18801.6311
CM-D45 C19H21N3O490.565.530.30.151.650.23
RY-09810.122.216.5ND1.68100
YT-50.4210.603436.06ND1.695ND
JYI-60 (C17H11N2OF)3.731.6354.3ND1.75000
RY-03314.85625.3ND1.7222.9
XHE-III-06a12151.837
SH-I-03014.4211.0419.09ND1.89ND
XLi352 C18H13ClN2O1.560.991NDND1.957ND
XLi351 C21H21ClN2OSi1.5070.967NDND1.985ND
XHE-III-142.6ND101327
DM-II-72 (C15H10N20BrCl)50001.37NDND2.025000
XHE-II-073B (S-ENRICHED)111712332.1269
FLUNITRAZEPAM2.22.54.5ND2.12000
XHE-III-7477105380.422.25.8
SVO-8-6774126152.3191
6-PBC0.491.212.2ND2.391343
RY-058864085ND2.4150
ZG-22417.133.750ND2.531.7
RY-066836048ND2.6180
RY-023 C22H27N3O3Si197142.62557.82.6158.6
XLi350 C17H11ClN2O1.2241.188NDND2.9ND
JYI-32 (C20H15N3O2BrF)3.074.96NDND2.9252.24
SH-I-89S12.788.5628.145ND3.23ND
MSR-I-0326.218.74ND3.374.9
OMB-19224.62033333.540
ZG-21312.849.830.2ND3.522.5
YT-II-8332.7413.2224.1ND3.548ND
RY-059897091ND3.7301
SPH-1210.141.191.72ND4479
RY-04720012479ND4340
XLI-8TC21.5211.012.155ND4.059ND
YT-I-38945.9326.8245.9ND4.07ND
DM-1466.44ND148 ND4.23247
CM-B44 (ss)3243123794.3485
CM-B4732633420074.4717
XLi-JY-DMH ANX33.30.581.9ND4.45000
WY-B-150.920.830.5820804.42646
ZK 934234.14.26ND4.51000
JYI-12 (C19H16N3O3F3)9139NDND4.56.8
CM-A871.624.5414.7310004.611000
DM-III-01 (C18H12N3O2Br)500012NDND4.735000
RY-057738597ND4.8333
JYI-15 (C19H14N3O3F3)205812NDND4.822
CM-B31i (ss)9018478184.9121
RY-079121.1141.9198.41595113.7
JC208 C15H10N2OS22.4218.89NDND5.039ND
YT-II6.9320.87123.518ND5.119ND
XLi270 C19H14N436.3925.81NDND5.291ND
XHE-I-051353942 ND5.3979
MMB-II-872003331071095.4333
XLI-2102316612666ND5.454.22
XHE-II-O53-ACID50.3511.844ND5.95000
ABECARNIL12.415.37.5ND61000
RY-I-31104519ND61000
QH-II-0821.71.81.6ND6.1100
SH-TSC-1 (PWZ-029)362.4180.3328.2ND6.185ND
XHE-II-0651000409216376.4175
JYI-49 (C20H12N3O2F4Br)1.872.38NDND6.73390
JC184 C13H9BrN2OS9.60610.5NDND6.709ND
QH-II-06676.342.147.420006.83000
XLI-381619.9285.63639ND7.051ND
RY-071195691ND7.2266
RY-I-28283318102ND7.261
CM-A82a2.788.9324.5110007.491000
YT-III-3136.3967.85129.7ND7.59ND
SH-I-047.36.1365.1ND7.664ND
QH-1460.49ND0.76ND7.71000
QH-II-0639.49.331ND7.73000
JC221 ANX1106.17549.405182ND7.7495362
DM-II-30 (C20H13N3O2BrF3)17.613.428.51ND7.85000
SH-TS-CH3107.250.0920.95ND8.068ND
RY-07315688122ND8.5267
SVO-8-20114028198.6138
SHU-221-1664143300093000
YT-III-23151.0961.4626.34ND9.124ND
CM-E09a1761921224909.2718
DM-1395.8ND169ND9.25325
YT-III-42382.916.8344.04ND9.77ND
CD-21416.448.242.5ND9.8168
XHE-III-240.25ND822210328
XLi223 C22H20BrN3O2148.7181000102000
SPH-1650.632.794.85ND10.41150
JYI-01 (C19H20N3O3Br)59.215996ND10.62.88
diazepam142015ND11ND
XHE-III-491.35.54.238.711.385.1
WZ-11319.213.213.4ND11.5300
JYI-59 (C22H13N3O2F4)1.082.611.82ND11.55000
JYI-72 (C22H21N4SiF)48.518.5NDND11.55000
TC-YT-II-76101.11.8975.816ND11.99ND
JYI-10 (C17H13N3O3F3Br)5000368NDND12.323
WZ-0694030.538.5ND12.61000
JYI-06 (C23H23N3O4)16.55.485000ND12.65000
RY-072220150184ND12.7361
JYI-14 (C17H14N3O3F3)3225NDND13565
XHE-II-0532874596150413.81000
Xli-347 C34H28N6O7828.05690.2NDND13.87ND
SHU-1-194127481484
CM-C28 (SR)17675224429014141
CM-E1133330816139414750
XHE-II-0124924311042142038
MMB-III-01811714078350014976
MMB-III-1811714078350014976
CM-B31c (ss)1183191733715137
CM-B4523055733626515230
XLI-093100010008581550152000
DM-II-20 (C22H14N3O2F3)54.327.1435.68ND15.355000
XLi269 C22H22N4Si221.8154.2NDND15.51ND
SH-O53-S-CH3-2′F3501411237ND165000
JYI-13 (C21H16N3O4F3)500063.7NDND168.38
CM-B3447245122311417175
XHE-II-0173.310725817294
JC222 C16H12N2OS86.745.11NDND17.63ND
SPH-3825.410.8ND18.53000
WZ-07072.730.753.2ND18.6300
RY-069692622506ND191000
SH-053-2′F-S-CH3468.233.27291.5ND19.2ND
XHE-I-09327.18.91107201162

Affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam or [3H] Ro15-4513 binding to HEK cell membranes expressing human receptors of compositions α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2, and α6β3γ2 [22, 139]. Data represent the average of at least three determinations with a SEM of ±5%. ND: not determined.

Cook code

CM-D45 C19H21N3O490.565.530.30.151.650.23
CM-D4434.356.320.70.330.570.92
JYI-04 (C21H23N3O3)28.316NDND0.511.57
PZII-0280.2ND0.2ND0.321.9
PWZ-009A11.341.311.26ND0.842.03
JYI-01 (C19H20N3O3Br)59.215996ND10.62.88
JYI-03 (C21H21N3O3)185.4107NDND0.9543.34
Ro15-45133.32.62.5ND0.263.8
TG-4-292.83.92.72.10.183.9
JYI-11 (C22H22N3O3F3Si)50005000NDND6483.97
QH-II-0770.060.080.05ND0.124
ZG-63A17.321.629.1ND0.654
ZG-2089.711.210.9ND0.384.6
OMB-183.91.23.417330.85
RY-024 C19H19N3O326.926.318.7ND0.45.1
ZG-2347.2522.149.84ND0.35.25
XHE-III-7477105380.422.25.8
JYI-12 (C19H16N3O3F3)9139NDND4.56.8
DM-2391.5ND0.53ND0.146.89
XHE-III-142.6ND101327
TG-4-298.310.26.9ND0.47.61
DM-2156.74ND7.42ND0.2938.28
JYI-13 (C21H16N3O4F3)500063.7NDND168.38
CGS98950.21NDNDNDND9.3
ZG-16811.210.79.2ND0.479.4
PWZ-007A0.110.10.09ND0.210
PZII-0290.34ND0.79ND0.5210
XHE-II-0240.090.180.32140.2411
XHE-II-0028.318133.91.511
BRETAZENIL0.350.640.2ND0.512.7
JYI-19 (C23H23N3O3S)2.176205NDND3412.7
SVO-8-1482586.90.914
SVO-8-301.15.35.32.80.615
WYS10 C14H9F3N2O20.883625.6ND548.715.3
QH-II-090 (CGS-8216)0.050.080.12ND0.2517
PWZ-00710.230.170.120.4417.31

The affinity of compounds at /BzR recombinant subtypes was measured by competition for [3H]flunitrazepam binding to HEK cell membranes expressing human receptors of compositions 132, 232, 332, 432, 532, and 632 [139]. Data represent the average of at least three determinations with a SEM of ±5%. ND: not determined.

12. The α1β3γ2 Receptor Subtype

The focus of this research was aimed at diazepam sensitive receptors; additional features to the α4β3γ2 and α6β3γ2 receptors were not identified (see Table 5, Figures 34 and 35). The major new feature identified for the α5β3γ2 receptor was a new pocket. This new lipophilic pocket was identified with SH-053-R-CH3 (15) and SH-053-S-CH3 (16) chiral enantionmers as well as the 2′F analogs [74, 135, 136].

13. The α2β3γ2 Receptor Subtype

See Table 6 and Figures 36 and 37.

14. The α3β3γ2 Receptor Subtype

See Table 7 and Figures 38 and 39.

15. The α4β3γ2 Receptor Subtype

See Table 8 and Figures 40 and 41.

16. The α5β3γ2 Receptor Subtype

The multiple volume contours displayed in Figures 3447 were created using the mvolume function (multiple volume contour function) in Sybyl and compounds with binding affinity at the receptor less than or equal to 20 nM. To create the overlays, first, the display (dsp) and contour (cnt) files were created for the α5β3γ2 receptor subtype and the α1β3γ2 receptor subtype by overlaying the compounds for each of these receptors (see Table 9 and Figures 4245). Using the mvolume function, a logical expression was entered to create the surfaces making up the union as well as the included volume for each receptor subtype itself. It is clear from the included volume overlay that the pocket is deeper for the α5 subtype, as determined previously [13, 2123, 110, 119]. The new pocket can be distinguished as the new yellow region of the α5β3γ2 subtype which is due to recently designed R-isomers by Huang [135], Poe and Li.

17. The α6β3γ2 Receptor Subtype

See Table 10 and Figures 46 and 47.

18. Updates to the Previous Model

In addition to the newly discovered pocket, the updated library of binding affinity led to two specific updates in the previous model (Figure 48).

19. QSAR

A nontraditional quantitative structure activity relationship (QSAR) approach was executed to observe steric and electrostatic preferences for each receptor subtype. A subset of the compounds used in each subtype pharmacophore/receptor model were chosen with a good cross section of scaffold variety. The compounds used in the COMFA maps are the imidazobenzodiazepines published previously [110, 137] and additionally alternative scaffolds which bound with <20 nM at the respective subtype [22].

The interest here was in creation of steric and electrostatic maps of the comparative molecular field analyses (COMFA) created from molecular spreadsheets. A variety of compounds selective for each subtype were selected and placed into a dataset used to build the CoMFA models. Activities ( values) were converted to logarithmic units for this study. A CoMFA descriptor set was created based on the –log () of over 70 structures. The goal was to derive an alternative three-dimensional shape of the receptor using biological activity of the most selective compounds. Structures were determined by crystal structure where available or by calculation. Charges were provided based on the Gasteiger-Huckel model. Conformations were kept consistent based on previous studies of low energy conformations [110]. It should be noted that this was not a traditional QSAR study as nonselective compounds were excluded. Therefore, values did not cross 3 log units. This was acceptable since the goal was not to create a predictive QSAR predictive algorithm, rather a map of the receptor based on sterics and electrostatics. Hydrogen acceptor radii were set to 3.0 and the hydrogen donor radii were set to 2.6 based on recommendations from Certara (Tripos). Analyses were executed using PLS (partial least squares). The details of modeling will be further discussed in the SI.

For each of the following QSAR models (Figures 4964), green areas represent desirable steric bulk and yellow represents undesirable steric bulk. Positive electrostatic contributions are represented by blue and negative electrostatic contributions are represented by red.

20. The α1β3γ2 Receptor Subtype

See Figures 4952.

21. The α2β3γ2 Receptor Subtype

See Figures 5356.

22. The α3β3γ2 Receptor Subtype

See Figures 5760.

23. The α5β3γ2 Receptor Subtype

From the CoMFA maps several observations (Figure 65) can be made. The yellow steric regions near in the α5β3γ2 map are unique. This illustrated that, in general, benzodiazepines lacking a pendant phenyl are more suited to targeting the α5 subtype. The region of the α1 subtype is most tolerable for compounds with steric interactions in this location while the α3 subtype receptor compounds prefer no steric interaction in this location. Negative electrostatics are most preferred by the pocket of the α2 and α5 receptors. In general, the α1 subtype receptor prefers molecules without a dipole. It should be noted that none of the analogs are ionic in nature and the charges for this model were provided by the Gasteiger-Huckel model. For this reason more emphasis is placed on the steric relationships which exclude interactions in the pharmacophores. In the future a QSAR study which includes nonbinding benzodiazepines in the data set along with activity data will permit the creation of a predictive algorithm which will be very useful in lead targeting (see Figures 6165).

24. Conclusion

Benzodiazepines, β-carbolines, and other classes of compounds readily target the receptors. The difficulty is finding subtype selective ligands, since there is no crystal structure of the Bz/-ergic site itself, just one composed of five beta-subunits which has no Bz site to date. The α5-BzR/ subunit has recently been shown to be important in the search to treat numerous cognition-based illnesses including Alzheimer’s, schizophrenia, bipolar, and depression, as well as more recently a bronchodilator, potentially important in the treatment of asthma. As an inverse agonist, PWZ-029 was able to counteract the memory-impairing effects of scopolamine, a muscarinic antagonist, in both object recognition tests and object retrieval tests in rodents, and was active in primates, as well as samaritan Alzheimer’s rats. The implications of these tests point to a use as a possible treatment for Alzheimer’s disease. The docking of PWZ-029 in the α5γ2 R-subunit details the interactions between the pharmacophore/receptor model binding site and this important negative allosteric modulator. Furthermore, α5-BzR/ positive allosteric modulator, SH-053-2′F-R-CH3, was shown to reverse deleterious effects in the MAM-model of schizophrenia. The recent discovery of α5-R in airway smooth muscle by Emala et al. has also lead to the testing of SH-053-2′F-R-CH3 as a bronchodilator. This SH-053-2′F-R-CH3 was found to be effective in relaxing preconstricted airway smooth muscle, as well as attenuating calcium-ion entry through the plasma membrane. In addition, XLi-093 (an α5 receptor antagonist), a potently binding α5-subtype selective bivalent ligand, has been shown to inhibit the α5-cognition deficits effected by diazepam and is a very good α5 benzodiazepine receptor site antagonist. It has also been shown to reverse the effects of α5 PAMs and NAMs in both rodent and primate models. These findings led to the exploration of the α5-binding pocket in the Milwaukee-based pharmacophore.

New features have been introduced to the unified pharmacophore/receptor model based on many substance classes that act at the diazepam sensitive and diazepam insensitive BzR binding sites of receptors. The major new feature identified for the α5β3γ2 receptor was a new pocket which was found by using pendant 6-phenyl benzodiazepines with a R-CH3 at the prochiral center at C4. Further enhancement of potency was achieved by addition of 2′-F or 2′-N substituent in the pendant phenyl ring at C-6. While these changes have led to enhanced subtype selective ligands, the overall development guided by this pharmacophore model described here has led to new agents with varying, fascinating pharmacological profiles, ranging from use in cognition-based diseases such as Alzheimer’s and schizophrenia, to use as a bronchodilator. This research on updating the Milwaukee-based pharmacophore/receptor model can be used in the rational design for improving the selectivity of α5 ligands. As the library of compounds increases, the data which follows can then be further evaluated and can lead to more insight to the identification of the possible roles each individual residue may have with the binding pocket.

The X-ray structure determination of the α5β3γ2 GABA(A) receptor is eagerly awaited, while that with five β3-subunits has been reported recently (Miller and Aricescu, Nature 2014). It is hoped that the proposed orientation may be used by others to gain additional insight into the potential mechanisms underlying binding and modulation at the Bz site, all of which will lead to a better understanding of the structure and function of GABA(A) receptors, ultimately targeted toward treatment of diseases.

25. Synthesis of Ligands with α5 BzR Subtype Selectivity

Briefly, bromoacetyl bromide was added to 2-aminobenzophenone 44, followed by treatment with methanol, which had been saturated with ammonia (g) under the cooling of an ice-water bath. The benzodiazepine, 45, was brominated to provide 46 and then reacted with ethyl isocyanoacetate to generate the imidazobenzodiazepine, 47. A much better one-pot process has now been devised using KtBuO at −30°C [140]. The bromide 48 was subjected to a Stille-type coupling to give DM-I-81 (9) [126]. This route (Scheme 1) can be executed on several hundred gram scales.

The benzodiazepine monomers were prepared by the method of Fryer and Gu [89, 141]. The isatoic anhydride was heated with sarcosine in dimethyl sulfoxide to provide amide 49. Bromination of 49 in a mixture of acetic acid, bromine, and sodium acetate afforded the corresponding monosubstituted bromide 50 in good yield. Deprotonation of 50 with lithium diisopropyl amide (LDA) in THF was followed by treatment with diethyl chlorophosphate to provide the intermediate enol phosphate. The enol phosphate was stirred with a solution of ethyl isocyanoacetate and LDA to yield the imidazo congener. Again, a better one-pot procedure has been developed using KtBuO at −30°C in place of LDA at 0°C. A Heck type coupling reaction was employed with the bromide 51 with bis(acetate)bis(triphenylphosphine)palladium(II) to provide the TMS-acetylene 52. Treatment of 52 with Bu4NF removed the trimethylsilyl group. Hydrolysis of the ester function of 53 provided the acid 54 in excellent yield and this material was dried scrupulously and subjected to a standard CDI-mediated coupling reaction to furnish bivalent ligand XLi-093 (4). The imidazobenzodiazepine diethyl diester XLi-356 (10) was obtained from XLi-093 (Scheme 2) in high yield via catalytic hydrogenation (Pd/C, H2).

26. Synthesis of Bivalents

Inverse agonist 53 was synthesized via the reported procedure. Hydrolysis of the ester function of 53 provided the acid 54 in excellent yield. This material was dried scrupulously and was subjected to a standard CDI-mediated coupling reaction to furnish bivalent ligands 4, 55, and 56 in 60% yield (Scheme 3) [13].

The acid 57, obtained from the ester 47, which was available from the literature [13], was stirred with CDI in DMF, followed by stirring with the required diol and DBU to provide bromide substituted dimers 58 or 59, respectively. They were converted into the trimethylsilylacetylenyl 60 or 61, respectively, under standard conditions (Pd-mediated, Heck-type coupling) [142]. The bisacetylene 62 or 63 (individually) was easily obtained by treatment of the trimethylsilyl ligand 60 or 61 with fluoride anion, as shown in Scheme 4.

27. Materials, Methods, and Experimental

27.1. Materials and General Instrumentation

Chemicals were purchased from Aldrich Chemical Co. or Tokyo Chemical Industries and were used without further purification except where otherwise noted. Anhydrous THF was distilled from sodium/benzophenone ketyl. TLC analyses were carried out on Merck Kieselgel 60 F254, and flash column chromatography was performed on silica gel 60b purchased from E. M. Laboratories. Melting points were taken on a Thomas-Hoover melting point apparatus or an Electrothermal Model IA8100 digital melting point apparatus and are reported uncorrected. NMR spectra were recorded on a Bruker 300 or 500 MHz multiple-probe spectrometer. Infrared spectra were recorded on a Nicolet DX FTIR BX V5.07 spectrometer or a Mattson Polaris IR-10400 instrument. Low-resolution mass spectral data (EI/CI) were obtained on a Hewlett-Packard 5985B GC-mass spectrometer, while high resolution mass spectral data were taken on a VG autospectrometer (Double Focusing High Resolution GC/Mass Spectrometer, UK). Microanalyses were performed on a CE Elantech EA1110 elemental analyzer. Methods of specific experiments can be found in corresponding cited works.

27.2. Competition Binding Assays

Competition binding assays were performed in a total volume of 0.5 mL of a 50 mM Tris-acetate at 4° degree centigrade for 1 hour using [3H]flunitrazepam as the radioligand. For these binding assays, 20–50 mg of membrane protein harvested with hypotonic buffer (50 mM Tris-acetate pH 7.4 at 4 degree) was incubated with the radiolabel as previously described [139, 143]. Nonspecific binding was defined as radioactivity bound in the presence of 100 μM diazepam and represented less than 20% of total binding. Membranes were harvested with a Brandel cell harvester followed by three ice-cold washes onto polyethyleneimine-pretreated (0.3%) Whatman GF/C filters. Filters were dried overnight and then soaked in Ecoscint A liquid scintillation cocktail (National Diagnostics; Atlanta, GA). Bound radioactivity was quantified by liquid scintillation counting. Membrane protein concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with bovine serum albumin as the standard.

27.3. Radioligand Binding Assays (Drs. McKernan and Atack) [12]

In brief, the affinity of compounds for human recombinant GABA(A) receptors was measured by competition binding using 0.5 nM [3H]flunitrazepam. Transfected HEK cells (beta2 gamma2 and desired alpha subtype) were harvested into phosphate-buffered saline, centrifuged at 3,000 g, and stored at −70°C until required. On the day of the assay, pellets were thawed and resuspended in sufficient volume of 50 mM Tris/acetate (pH 7.4 at 4°C) to give a total binding of approximately 1500–2000 dpm. Nonspecific binding was defined in the presence of 100 mM (final concentration) diazepam. Test compounds were dissolved in DMSO at a concentration of 10 mM and diluted in assay buffer to give an appropriate concentration range in the assay, such that the final DMSO concentration in the assay was always less than 1%. Total assay volume was 0.5 mL and assays were carried out in 96-well plates and incubation time started by the addition of 0.1 mL of resuspended cell membranes. Following incubation for 1 hour at 4°C, assays were terminated by filtration through GF/B filters, washed with 10 mL ice cold buffer, dried, and then counted using a liquid scintillation counter. The percentage of inhibition of [3H]flunitrazepam binding, the IC50, and the values were calculated using the Activity Base Software Package (ID Business Solutions, Guildford, UK) according to the Cheng-Prusoff equation [143]. We have previously reported the synthesis of the following.

1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 4 (XLi-093) (Procedure A), experimental details previously reported [17].

1,5-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxy) pentyl diester 56 (XLi-210), experimental details previously reported [17].

1,3-Bis(8-ethyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxy) propyl diester 10 (Xli-356), experimental previously published [144].

Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxy) dimethyl glycol diester 55 (Xli-374), experimental details previously reported [17].

8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic acid 57, experimental details previously reported [17].

1,3-Bis(8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxy) propyl diester 59 (DMH-D-070) (Procedure B), experimental details previously reported [17].

1,3-Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]-diazepine-3-carboxy) propyl diester 61 (DMH-D-048) (Procedure C), experimental details previously reported [17].

1,3-Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxy) propyl diester 63 (DMH-D-053): experimental details previously reported [17].

Bis(8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxy) diethylene glycol diester 58 (DM-III-93), experimental details previously reported [17].

Bis(8-trimethylsilylacetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxy) diethylene glycol diester 60 (DM-III-94), experimental details previously reported [17].

Bis(8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxy) diethylene glycol diester 62 (DM-III-96), experimental details previously reported [17].

Abbreviations

APD:Antipsychotic drug
ASM:Airway smooth muscle
BS:Binding site
BZD, Bz:Benzodiazepine
BzR:Benzodiazepine receptor
DA:Dopamine
DAPI:4′,6-Diamidino-2-phenylindole
GABA:Gamma amino butyric acid
:Gamma amino butyric acid A
R:Gamma amino butyric acid A receptor
HAL:Haloperidol
HEK:Human embryonic kidney
HPC:Hippocampal
LTK:Leukocyte tyrosine kinase
MAM:Methylazoxymethanol
NAM:Negative allosteric modulator
QSAR:Quantitative structure-activity relationship
PAM:Positive allosteric modulator
PV:Parvalbumin
SAL:Saline
SH-053:SH-053-2′F-R-CH3
SMA:Smooth muscle actin
TTX:Tetrodotoxin
VTA:Ventral tegmental area.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Terry Clayton and Michael M. Poe contributed equally to this work.

Acknowledgments

The authors gratefully acknowledge the work of Dr. Ruth McKernan and Dr. Bryan Roth for receptor binding. This was supported by NS-076517, MH-096463, NIA AG-039511, and AG-048446. The authors acknowledge support from the Milwaukee Institute for Drug Design.

Supplementary Materials

The supporting information contains details on the construction of the Unified Pharmacophore/Receptor Model. In addition, the crystallographic data (excluding structure factors) for the structures in this report have been deposited with the Cambridge Crysallographic Data Centre as supplementary publication numbers 687205 (DMH-D-053), 222395 (XLi-093), and 222396 (DM-II-96). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax +44-(0)1223-336033 or email: deposit@ccdc.cam.ac.uk). Structures of all compounds found within Tables 5-9 are also contained within the supporting information under Appendix III.

  1. Supplementary Material

References

  1. P. S. Miller and A. R. Aricescu, “Crystal structure of a human GABAA receptor,” Nature, vol. 512, no. 7514, pp. 270–275, 2014. View at: Publisher Site | Google Scholar
  2. K. H. Backus, M. Arigoni, U. Drescher et al., “Stoichiometry of a recombinant GABAA receptor deduced from mutation-induced rectification,” Neuroreport, vol. 5, no. 3, pp. 285–288, 1993. View at: Google Scholar
  3. H. Möhler, “Brain disorders and novel therapeutics,” Chimia, vol. 58, no. 10, pp. 718–720, 2004. View at: Publisher Site | Google Scholar
  4. H. Möhler, J.-M. Fritschy, F. Crestani, T. Hensch, and U. Rudolph, “Specific GABAA circuits in brain development and therapy,” Biochemical Pharmacology, vol. 68, no. 8, pp. 1685–1690, 2004. View at: Publisher Site | Google Scholar
  5. U. Rudolph and H. Möhler, “Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics,” Annual Review of Pharmacology and Toxicology, vol. 44, pp. 475–498, 2004. View at: Publisher Site | Google Scholar
  6. D. J. Bailey, J. E. Tetzlaff, J. M. Cook, X. He, and F. J. Helmstetter, “Effects of hippocampal injections of a novel ligand selective for the α5β2γ2 subunits of the GABA/benzodiazepine receptor on Pavlovian conditioning,” Neurobiology of Learning and Memory, vol. 78, no. 1, pp. 1–10, 2002. View at: Publisher Site | Google Scholar
  7. T. M. DeLorey, R. C. Lin, B. McBrady et al., “Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory,” European Journal of Pharmacology, vol. 426, no. 1-2, pp. 45–54, 2001. View at: Publisher Site | Google Scholar
  8. M. S. Chambers, J. R. Atack, F. A. Bromidge et al., “6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A α5 receptor inverse agonists,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1176–1179, 2002. View at: Publisher Site | Google Scholar
  9. M. S. Chambers, J. R. Atack, H. B. Broughton et al., “Identification of a novel, selective GABAa α5 receptor inverse agonist which enhances cognition,” Journal of Medicinal Chemistry, vol. 46, no. 11, pp. 2227–2240, 2003. View at: Publisher Site | Google Scholar
  10. C. Sur, K. Quirk, D. Dewar, J. Atack, and R. Mckernan, “Rat and human hippocampal alpha 5 subunit-containing gamma-aminobutyric acid(A) receptors have alpha 5 beta 3 gamma 2 pharmacological characteristics,” Molecular Pharmacology, vol. 54, no. 5, pp. 928–933, 1998. View at: Google Scholar
  11. M. Sarter, “Taking stock of cognition enhancers,” Trends in Pharmacological Sciences, vol. 12, pp. 456–461, 1991. View at: Publisher Site | Google Scholar
  12. J. R. Atack, L. Alder, S. M. Cook, A. J. Smith, and R. M. McKernan, “In vivo labelling of α5 subunit-containing GABAA receptors using the selective radioligand [3H]L-655,708,” Neuropharmacology, vol. 49, no. 2, pp. 220–229, 2005. View at: Publisher Site | Google Scholar
  13. X. Y. Li, H. Cao, C. C. Zhang et al., “Synthesis, in vitro affinity, and efficacy of a bis 8-ethynyl-4H-imidazo[1,5α]-[1,4]benzodiazepine analogue, the first bivalent α5 subtype selective BzR/GABAA antagonist,” Journal of Medicinal Chemistry, vol. 46, no. 26, pp. 5567–5570, 2003. View at: Publisher Site | Google Scholar
  14. X. Li, Synthesis of selective ligands for GABAA/benzodiazepine receptors [Ph.D. thesis], University of Wisconsin-Milwaukee, Milwaukee, Wis, USA, 2004.
  15. A. H. Abadi, S. Lankow, B. Hoefgen, M. Decker, M. U. Kassack, and J. Lehmann, “Dopamine/serotonin receptor ligands, part III: synthesis and biological activities of 7,7′-alkylene-bis-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecines—application of the bivalent ligand approach to a novel type of dopamine receptor antagonist,” Archiv der Pharmazie, vol. 335, no. 8, pp. 367–373, 2002. View at: Google Scholar
  16. W. Yin, F. Rivas, R. Furtmueller et al., “Synthesis, in-vitro affinity and efficacy of the first bivalent alpha 5 subtype selective BzR/GABA(A) antagonist,” in Proceedings of the 2004 Neuroscience Meeting, San Diego, Calif, USA, 2004. View at: Google Scholar
  17. D. Han, F. Holger Försterling, X. Li et al., “A study of the structure-activity relationship of GABAA-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis,” Bioorganic and Medicinal Chemistry, vol. 16, no. 19, pp. 8853–8862, 2008. View at: Publisher Site | Google Scholar
  18. D. M. Han, F. H. Försterling, X. Y. Li, J. R. Deschamps, H. Cao, and J. M. Cook, “Determination of the stable conformation of GABAA-benzodiazepine receptor bivalent ligands by low temperature NMR and X-ray analysis,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 6, pp. 1465–1469, 2004. View at: Publisher Site | Google Scholar
  19. C. C. Zhang, Structure Activity Relationships and Cytotoxic Activity of Analogs of Tryprostatin A and B. Preparation of Irreversible Inhibitors for Studies of Mechanism and Action. II. Pharmacophore Receptor Models of GABA(A)/BzR, University of Wisconsin-Milwaukee, Milwaukee, Wis, USA, 2004.
  20. R. Y. Liu, R. J. Hu, P. W. Zhang, P. Skolnick, and J. M. Cook, “Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for α5-containing GABAA receptors,” Journal of Medicinal Chemistry, vol. 39, no. 9, pp. 1928–1934, 1996. View at: Publisher Site | Google Scholar
  21. Q. Huang, X. H. He, C. R. Ma et al., “Pharmacophore/receptor models for GABAA/BzR subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a comprehensive ligand-mapping approach,” Journal of Medicinal Chemistry, vol. 43, no. 1, pp. 71–95, 2000. View at: Publisher Site | Google Scholar
  22. T. Clayton, Part I. Unified pharmacophore protein models of the benzodiazepine receptor subtypes. Part II. Subtype selective ligands for alpha5 Gaba(A) /BZ receptors [Ph.D. thesis], University of Wisconsin-Milwaukee, Milwaukee, Wis, USA, 2011.
  23. T. Clayton, J. L. Chen, M. Ernst et al., “An updated unified pharmacophore model of the benzodiazepine binding site on γ-aminobutyric acida receptors: correlation with comparative models,” Current Medicinal Chemistry, vol. 14, no. 26, pp. 2755–2775, 2007. View at: Publisher Site | Google Scholar
  24. M. M. Savić, T. Clayton, R. Furtmüller et al., “PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA-A receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats,” Brain Research, vol. 1208, pp. 150–159, 2008. View at: Publisher Site | Google Scholar
  25. M. Milić, T. Timić, S. Joksimović et al., “PWZ-029, an inverse agonist selective for α5 GABAA receptors, improves object recognition, but not water-maze memory in normal and scopolamine-treated rats,” Behavioural Brain Research, vol. 241, no. 1, pp. 206–213, 2013. View at: Publisher Site | Google Scholar
  26. J. K. Rowlett, C. A. Moran, T. Clayton, S. Rallapalli, B. Roth, and J. M. Cook, PWZ-029, An Inverse Agonist Selective for α5 Subunit Containing GABA(A) Receptors, Enhances Performance on an Executive Function Task in Monkeys, European Behavioral Pharmacology Society, Rome, Italy, 2009.
  27. F. M. Benes, B. Lim, D. Matzilevich, J. P. Walsh, S. Subburaju, and M. Minns, “Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10164–10169, 2007. View at: Publisher Site | Google Scholar
  28. L. M. Rimol, C. B. Hartberg, R. Nesvåg et al., “Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder,” Biological Psychiatry, vol. 68, no. 1, pp. 41–50, 2010. View at: Publisher Site | Google Scholar
  29. C. Pantelis, D. Velakoulis, P. D. McGorry et al., “Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison,” The Lancet, vol. 361, no. 9354, pp. 281–288, 2003. View at: Publisher Site | Google Scholar
  30. S. A. Schobel, M. A. Kelly, C. M. Corcoran et al., “Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia,” Schizophrenia Research, vol. 114, no. 1–3, pp. 110–118, 2009. View at: Publisher Site | Google Scholar
  31. S. A. Schobel, N. M. Lewandowski, C. M. Corcoran et al., “Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders,” Archives of General Psychiatry, vol. 66, no. 9, pp. 938–946, 2009. View at: Publisher Site | Google Scholar
  32. A. P. Weiss, D. Goff, D. L. Schacter et al., “Fronto-hippocampal function during temporal context monitoring in schizophrenia,” Biological Psychiatry, vol. 60, no. 11, pp. 1268–1277, 2006. View at: Publisher Site | Google Scholar
  33. R. C. Wolf, A. Höse, K. Frasch, H. Walter, and N. Vasic, “Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia,” European Psychiatry, vol. 23, no. 8, pp. 541–548, 2008. View at: Publisher Site | Google Scholar
  34. H. Moore, J. D. Jentsch, M. Ghajarnia, M. A. Geyer, and A. A. Grace, “A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia,” Biological Psychiatry, vol. 60, no. 3, pp. 253–264, 2006. View at: Publisher Site | Google Scholar
  35. P. Flagstad, A. Mørk, B. Y. Glenthøj, J. Van Beek, A. T. Michael-Titus, and M. Didriksen, “Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens,” Neuropsychopharmacology, vol. 29, no. 11, pp. 2052–2064, 2004. View at: Publisher Site | Google Scholar
  36. D. J. Lodge and A. A. Grace, “Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia,” The Journal of Neuroscience, vol. 27, no. 42, pp. 11424–11430, 2007. View at: Publisher Site | Google Scholar
  37. D. J. Lodge, M. M. Behrens, and A. A. Grace, “A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia,” The Journal of Neuroscience, vol. 29, no. 8, pp. 2344–2354, 2009. View at: Publisher Site | Google Scholar
  38. K. M. Gill, D. J. Lodge, J. M. Cook, S. Aras, and A. A. Grace, “A novel α5GABAAR-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia,” Neuropsychopharmacology, vol. 36, no. 9, pp. 1903–1911, 2011. View at: Publisher Site | Google Scholar
  39. W. Zhang, K. F. Koehler, P. Zhang, and J. M. Cook, “Development of a comprehensive pharmacophore model for the benzodiazepine receptor,” Drug Design and Discovery, vol. 12, no. 3, pp. 193–248, 1995. View at: Google Scholar
  40. W. Zhang, H. Diaz-Arauzo, M. S. Allen, K. F. Koehler, and J. M. Cook, “Chemical and computer assisted development of the inclusive pharmacophore of benzodiazepine receptors,” in Studies in Medicinal Chemistry, M. I. Choudhary, Ed., p. 303, Harwood Academic Publishers, 1996. View at: Google Scholar
  41. P. W. Zhang, W. J. Zhang, R. Y. Liu, B. Harris, P. Skolnick, and J. M. Cook, “Synthesis and SAR study of novel imidazobenzodiazepines at ‘diazepam-insensitive’ benzodiazepine receptors,” Journal of Medicinal Chemistry, vol. 38, no. 10, pp. 1679–1688, 1995. View at: Google Scholar
  42. Q. Huang, E. D. Cox, T. Gan et al., “Studies of molecular pharmacophore/receptor models for GABA(A)/benzodiazepine receptor subtypes: binding affinities of substituted β-carbolines at recombinant α1β3γ2 subtypes and quantitative structure-activity relationship studies via a comparative molecular field analysis,” Drug Design and Discovery, vol. 16, no. 1, pp. 55–76, 1999. View at: Google Scholar
  43. D. Harris, T. Clayton, J. Cook et al., “Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the α5 subunit,” Journal of Medicinal Chemistry, vol. 51, no. 13, pp. 3788–3803, 2008. View at: Publisher Site | Google Scholar
  44. D. Rüedi-Bettschen, J. K. Rowlett, S. Rallapalli, T. Clayton, J. M. Cook, and D. M. Platt, “Modulation of α5 subunit-containing GABAA receptors alters alcohol drinking by rhesus monkeys,” Alcoholism: Clinical and Experimental Research, vol. 37, no. 4, pp. 624–634, 2013. View at: Publisher Site | Google Scholar
  45. M. M. Savić, M. M. Milinković, S. Rallapalli et al., “The differential role of alpha1- and alpha5-containing GABAA receptors in mediating diazepam effects on spontaneous locomotor activity and water-maze learning and memory in rats,” International Journal of Neuropsychopharmacology, vol. 12, no. 9, pp. 1179–1193, 2009. View at: Publisher Site | Google Scholar
  46. X. Y. Li, C. R. Ma, X. H. He et al., “Studies in search of diazepam-insensitive subtype selective agents for GABAA/Bz receptors,” Medicinal Chemistry Research, vol. 11, no. 9, pp. 504–537, 2003. View at: Google Scholar
  47. L. Duggan, M. Fenton, J. Rathbone, R. Dardennes, A. El-Dosoky, and S. Indran, “Olanzapine for schizophrenia,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD001359, 2005. View at: Google Scholar
  48. J. A. Lieberman, T. S. Stroup, J. P. McEvoy et al., “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1209–1223, 2005. View at: Publisher Site | Google Scholar
  49. K. Komossa, C. Rummel-Kluge, H. Hunger et al., “Olanzapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD006654, 2010. View at: Google Scholar
  50. K. Komossa, C. Rummel-Kluge, H. Hunger et al., “Zotepine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, p. CD006628, 2010. View at: Google Scholar
  51. K. Komossa, C. Rummel-Kluge, H. Hunger et al., “Amisulpride versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, p. CD006624, 2010. View at: Google Scholar
  52. K. Komossa, C. Rummel-Kluge, F. Schmid et al., “Quetiapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD006625, 2010. View at: Google Scholar
  53. C. Sur, L. Fresu, O. Howell, R. M. McKernan, and J. R. Atack, “Autoradiographic localization of α5 subunit-containing GABA(A) receptors in rat brain,” Brain Research, vol. 822, no. 1-2, pp. 265–270, 1999. View at: Publisher Site | Google Scholar
  54. H. L. June, S. C. Harvey, K. L. Foster et al., “GABAA receptors containing α5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry,” The Journal of Neuroscience, vol. 21, no. 6, pp. 2166–2177, 2001. View at: Google Scholar
  55. A. Lingford-Hughes, S. P. Hume, A. Feeney et al., “Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography,” Journal of Cerebral Blood Flow and Metabolism, vol. 22, no. 7, pp. 878–889, 2002. View at: Google Scholar
  56. B. Hutcheon, J. M. Fritschy, and M. O. Poulter, “Organization of GABAA receptor alpha-subunit clustering in the developing rat neocortex and hippocampus,” European Journal of Neuroscience, vol. 19, no. 9, pp. 2475–2487, 2004. View at: Publisher Site | Google Scholar
  57. B. Ramos, J. F. Lopez-Tellez, J. Vela et al., “Expression of α5 GABAA receptor subunit in developing rat hippocampus,” Developmental Brain Research, vol. 151, no. 1-2, pp. 87–98, 2004. View at: Publisher Site | Google Scholar
  58. S. K. Towers, T. Gloveli, R. D. Traub et al., “Alpha5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro,” Journal of Physiology, vol. 559, no. 3, pp. 721–728, 2004. View at: Publisher Site | Google Scholar
  59. S. A. Heldt and K. J. Ressler, “Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization,” Neuroscience, vol. 150, no. 2, pp. 370–385, 2007. View at: Publisher Site | Google Scholar
  60. C. Papatheodoropoulos and E. Koniaris, “α5GABAA receptors regulate hippocampal sharp wave-ripple activity in vitro,” Neuropharmacology, vol. 60, no. 4, pp. 662–673, 2011. View at: Publisher Site | Google Scholar
  61. K. M. Gill, J. M. Cook, M. M. Poe, and A. A. Grace, “Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia,” Schizophrenia Bulletin, vol. 40, no. 2, pp. 341–350, 2014. View at: Publisher Site | Google Scholar
  62. C. C. Kaczorowski and J. F. Disterhoft, “Memory deficits are associated with impaired ability to modulate neuronal excitability in middle-aged mice,” Learning and Memory, vol. 16, no. 6, pp. 362–366, 2009. View at: Publisher Site | Google Scholar
  63. C. C. Kaczorowski, E. Sametsky, S. Shah, R. Vassar, and J. F. Disterhoft, “Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease,” Neurobiology of Aging, vol. 32, no. 8, pp. 1452–1465, 2011. View at: Publisher Site | Google Scholar
  64. C. C. Kaczorowski, S. J. Davis, and J. R. Moyer Jr., “Aging redistributes medial prefrontal neuronal excitability and impedes extinction of trace fear conditioning,” Neurobiology of Aging, vol. 33, no. 8, pp. 1744–1757, 2012. View at: Publisher Site | Google Scholar
  65. S. I. Rallapalli, Synthesis of Agents to Enhance Cognition. II. Synthesis of Indole Alkaloids, University of Wisconsin-Milwaukee, 2014.
  66. P. J. Barnes, “Biochemistry of asthma,” Trends in Biochemical Sciences, vol. 16, pp. 365–369, 1991. View at: Publisher Site | Google Scholar
  67. D. W. Cockcroft, “Clinical concerns with inhaled β2-agonists: adult asthma,” Clinical Reviews in Allergy and Immunology, vol. 31, no. 2-3, pp. 197–208, 2006. View at: Publisher Site | Google Scholar
  68. R. W. Morton, M. L. Everard, and H. E. Elphick, “Adherence in childhood asthma: the elephant in the room,” Archives of Disease in Childhood, vol. 99, no. 10, pp. 949–953, 2014. View at: Publisher Site | Google Scholar
  69. N. S. Jentzsch, P. Camargos, E. S. C. Sarinho, and J. Bousquet, “Adherence rate to beclomethasone dipropionate and the level of asthma control,” Respiratory Medicine, vol. 106, no. 3, pp. 338–343, 2012. View at: Publisher Site | Google Scholar
  70. E. K. Chu and J. M. Drazen, “Asthma: one hundred years of treatment and onward,” The American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 11, pp. 1202–1208, 2005. View at: Publisher Site | Google Scholar
  71. G. Gallos, N. R. Gleason, Y. Zhang et al., “Activation of endogenous GABAA channels on airway smooth muscle potentiates isoproterenol-mediated relaxation,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 295, no. 6, pp. L1040–L1047, 2008. View at: Publisher Site | Google Scholar
  72. K. Mizuta, D. Xu, Y. Pan et al., “GABAA receptors are expressed and facilitate relaxation in airway smooth muscle,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 294, no. 6, pp. L1206–L1216, 2008. View at: Publisher Site | Google Scholar
  73. M. M. Savić, T. Clayton, R. Furtmüller et al., “PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats,” Brain Research, vol. 1208, pp. 150–159, 2008. View at: Publisher Site | Google Scholar
  74. M. M. Savić, S. Huang, R. Furtmüller et al., “Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?” Neuropsychopharmacology, vol. 33, no. 2, pp. 332–339, 2008. View at: Publisher Site | Google Scholar
  75. G. Gallos, G. T. Yocum, M. E. Siviski et al., “Selective targeting of the α5 subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 308, no. 9, pp. L931–L942, 2015. View at: Publisher Site | Google Scholar
  76. M. S. Allen, Y.-C. Tan, M. L. Trudell et al., “Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site,” Journal of Medicinal Chemistry, vol. 33, no. 9, pp. 2343–2357, 1990. View at: Publisher Site | Google Scholar
  77. M. S. Allen, T. J. Hagen, M. L. Trudell, P. W. Codding, P. Skolnick, and J. M. Cook, “Synthesis of novel 3-substituted β-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore,” Journal of Medicinal Chemistry, vol. 31, no. 9, pp. 1854–1861, 1988. View at: Publisher Site | Google Scholar
  78. H. Diaz-Arauzo, G. E. Evoniuk, P. Skolnick, and J. M. Cook, “The agonist pharmacophore of the benzodiazepine receptor. Synthesis of a selective anticonvulsant/anxiolytic,” Journal of Medicinal Chemistry, vol. 34, no. 5, pp. 1754–1756, 1991. View at: Publisher Site | Google Scholar
  79. H. Diaz-Arauzo, K. F. Koehler, T. J. Hagen, and J. M. Cook, “Synthetic and computer assisted analysis of the pharmacophore for agonists at benzodiazepine receptors,” Life Sciences, vol. 49, no. 3, pp. 207–216, 1991. View at: Publisher Site | Google Scholar
  80. W. J. Zhang, K. F. Koehler, B. Harris, P. Skolnick, and J. M. Cook, “Synthesis of benzo-fused benzodiazepines employed as probes of the agonist pharmacophore of benzodiazepine receptors,” Journal of Medicinal Chemistry, vol. 37, no. 6, pp. 745–757, 1994. View at: Publisher Site | Google Scholar
  81. M. L. Trudell, S. L. Lifer, Y.-C. Tan et al., “Synthesis of substituted 7,12-dihydropyrido[3,2-b:5,4-b′]diindoles: rigid planar benzodiazepine receptor ligands with inverse agonist/antagonist properties,” Journal of Medicinal Chemistry, vol. 33, no. 9, pp. 2412–2420, 1990. View at: Publisher Site | Google Scholar
  82. M. L. Trudell, A. S. Basile, H. E. Shannon, P. Skolnick, and J. M. Cook, “Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b′]diindoles. A novel class of rigid, planar benzodiazepine receptor ligands,” Journal of Medicinal Chemistry, vol. 30, no. 3, pp. 456–458, 1987. View at: Publisher Site | Google Scholar
  83. M. J. Frisch, G. W. Trucks, M. Head-Gordon et al., Gaussian 92, Gaussian, Pittsburgh, Pa, USA, 1992, http://www.lct.jussieu.fr/manuels/Gaussian98/00000119.htm.
  84. M. L. I. Trudell, The synthesis and study of the pharmacologic activity of 7,12 dihydropyrido[3,2 b:5,4 b′]diindoles. A novel class of rigid, planar benzodiazepine receptor ligands. II. The total synthesis of the indole alkaloid, (±) suaveoline [Ph.D. thesis], University of Wisconsin-Milwaukee, Milwaukee, Wis, USA, 1989.
  85. W. Yin, S. Majumder, T. Clayton et al., “Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse,” Bioorganic and Medicinal Chemistry, vol. 18, no. 21, pp. 7548–7564, 2010. View at: Publisher Site | Google Scholar
  86. D. Han, F. H. Forsterling, X. Li, J. Deschamps, H. Cao, and J. M. Cook, “Study of the structure activity relationships of GABAA-benzodiazepine receptor ligands by low termperature NMR spectroscopy and X-ray analysis,” in Proceedings of the 227th ACS National Meeting, Anaheim, Calif, USA, March-April 2004. View at: Google Scholar
  87. B. D. Fischer, S. C. Licata, H. Zhou et al., “Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure,” Neuropharmacology, vol. 59, no. 7-8, pp. 612–618, 2010. View at: Publisher Site | Google Scholar
  88. W. Haefely, E. Kyburz, M. Gerecke, and H. Mohler, “Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure—activity relationships of their agonist and antagonists,” in Advances in Drug Research, vol. 99, pp. 165–322, Academic Press, New York, NY, USA, 1985. View at: Google Scholar
  89. R. I. Fryer, Z.-Q. Gu, and C.-G. Wang, “Synthesis of novel, substituted 4H-imidazo[1,5-a][1,4]benzodiazepines,” Journal of Heterocyclic Chemistry, vol. 28, no. 7, pp. 1661–1669, 1991. View at: Publisher Site | Google Scholar
  90. R. I. Fryer, P. Zhang, R. Rios, Z.-Q. Gu, A. S. Basile, and P. Skolnick, “Structure-activity relationship studies at the benzodiazepine receptor (Bzr)—a comparison of the substituent effects of pyrazoloquinolinone analogs,” Journal of Medicinal Chemistry, vol. 36, no. 11, pp. 1669–1673, 1993. View at: Publisher Site | Google Scholar
  91. F. M. Rivas, C. R. Edwankar, J. M. Cook et al., “Antiseizure activity of novel γ-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models,” Journal of Medicinal Chemistry, vol. 52, no. 7, pp. 1795–1798, 2009. View at: Publisher Site | Google Scholar
  92. J. M. Cook, D. Han, X. He et al., “Anxiolytic agents with reduced sedative and ataxic effects,” 7119196 B2, 2006. View at: Google Scholar
  93. J. M. Cook, H. Zhao, S. Huang, P. S. Sarma, and C. C. Zhang, “Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects,” US Patent 2006004945, 2007. View at: Google Scholar
  94. R. I. Fryer, Comprehensive Medicinal Chemistry, vol. 99, Pergamon Press, Oxford, UK, 1989.
  95. H. O. Villar, M. F. Davies, G. H. Loew, and P. A. Maguire, “Molecular models for recognition and activation at the benzodiazepine receptor: a review,” Life Sciences, vol. 48, no. 7, pp. 593–602, 1991. View at: Publisher Site | Google Scholar
  96. H. O. Villar, E. T. Uyeno, L. Toll, W. Polgar, M. F. Davies, and G. H. Loew, “Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities,” Molecular Pharmacology, vol. 36, no. 4, pp. 589–600, 1989. View at: Google Scholar
  97. G. M. Crippen, “Distance geometry analysis of the benzodiazepine binding site,” Molecular Pharmacology, vol. 22, no. 1, pp. 11–19, 1982. View at: Google Scholar
  98. A. K. Ghose and G. M. Crippen, “Modeling the benzodiazepine receptor binding site by the general three-dimensional structure-directed quantitative structure-activity relationship method REMOTEDISC,” Molecular Pharmacology, vol. 37, no. 5, pp. 725–734, 1990. View at: Google Scholar
  99. P. W. Codding and A. K. S. Muir, “Molecular structure of Ro15-1788 and a model for the binding of benzodiazepine receptor ligands. Structural identification of common features in antagonists,” Molecular Pharmacology, vol. 28, no. 2, pp. 178–184, 1985. View at: Google Scholar
  100. A. K. S. Muir and P. W. Codding, “Structure-activity studies of β-carbolines. 3. Crystal and molecular structures of methyl β-carboline-3-carboxylate,” Canadian Journal of Chemistry, vol. 63, no. 10, pp. 2752–2756, 1985. View at: Publisher Site | Google Scholar
  101. M. G. Codding, A. W. Roszak, M. B. Szkaradzinska, J. M. Cook, and L. J. Aha, Modeling of the Benzodiazepine Receptor Using Structural and Theoretical Characterization of Novel Beta-Carbolines, Elsevier Science, Amsterdam, The Netherlands, 1989.
  102. V. Ferretti, P. Gilli, and P. A. Borea, “Structural features controlling the binding of β-carbolines to the benzodiazepine receptor,” Acta Crystallographica Section B: Structural Science, vol. 60, no. 4, pp. 481–489, 2004. View at: Publisher Site | Google Scholar
  103. P. A. Borea, G. Gilli, V. Bertolasi, and V. Ferretti, “Stereochemical features controlling binding and intrinsic activity properties of benzodiazepine-receptor ligands,” Molecular Pharmacology, vol. 31, no. 4, pp. 334–344, 1987. View at: Google Scholar
  104. V. Bertolasi, V. Feretti, G. Gilli, and P. A. Borea, “Stereochemistry of benzodiazepine-receptor ligands.1. Structure of methyl beta-carboline-3-carboxylate (beta-CCM), C13H10N2O2,” Acta Crystallographica Section C: Crystal Structure Communications, vol. 40, p. 1981, 1984. View at: Google Scholar
  105. V. Ferretti, V. Bertolasi, G. Gilli, and P. A. Borea, “Structures of two 2-arylpyrazolo[4,3-c]quinolin-3-ones: CGS8216, C16H11N3O, and CGS9896, C16H10ClN3O,” Acta Crystallographica Section C: Crystal Structure Communications, vol. 41, no. 1, pp. 107–110, 1985. View at: Publisher Site | Google Scholar
  106. S. Tebib, J.-J. Bourguignon, and C.-G. Wermuth, “The active analog approach applied to the pharmacophore identification of benzodiazepine receptor ligands,” Journal of Computer-Aided Molecular Design, vol. 1, no. 2, pp. 153–170, 1987. View at: Publisher Site | Google Scholar
  107. C. R. Gardner, “A review of recently-developed ligands for neuronal benzodiazepine receptors and their pharmacological activities,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 16, no. 6, pp. 755–781, 1992. View at: Publisher Site | Google Scholar
  108. M. S. Allen, A. J. LaLoggia, L. J. Dorn et al., “Predictive binding of β-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach,” Journal of Medicinal Chemistry, vol. 35, no. 22, pp. 4001–4010, 1992. View at: Publisher Site | Google Scholar
  109. Q. Huang, E. Cox, T. Gan et al., “Studies of molecular pharmacophore/receptor models for GABAA/benzodiazepine receptor subtypes: binding affinities of substituted β-carbolines at recombinant alpha x beta 3 gamma 2 subtypes and quantitative structure-activity relationship studies via a comparative molecular field analysis,” Drug Design and Discovery, vol. 16, no. 1, pp. 55–76, 1999. View at: Google Scholar
  110. X. He, Q. Huang, C. Ma, S. Yu, R. McKernan, and J. M. Cook, “Pharmacophore/receptor models for GABA(A)/BzR α2β3γ2, α3β3γ2 and α4β3γ2 recombinant subtypes. Included volume analysis and comparison to α1β3γ2, α5β3γ2 and α6β3γ2 subtypes,” Drug Design and Discovery, vol. 17, no. 2, pp. 131–171, 2000. View at: Google Scholar
  111. E. D. Cox, H. Diaz-Arauzo, Q. Huang et al., “Synthesis and evaluation of analogues of the partial agonist 6- (propyloxy)-4-(methoxymethyl)-β-carboline-3-carboxylic acid ethyl ester (6- PBC) and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-β-carboline-3-carboxylic acid ethyl ester (Zk 93423) at wild type and recombinant GABA(A) receptors,” Journal of Medicinal Chemistry, vol. 41, no. 14, pp. 2537–2552, 1998. View at: Publisher Site | Google Scholar
  112. M. J. Martin, M. L. Trudell, H. D. Araúzo et al., “Molecular yardsticks—rigid probes to define the spatial dimensions of the benzodiazepine receptor binding site,” Journal of Medicinal Chemistry, vol. 35, no. 22, pp. 4105–4117, 1992. View at: Publisher Site | Google Scholar
  113. K. Naryanan and J. M. Cook, “Probing the dimensions of the benzodiazepine receptor inverse agonist site,” Heterocycles, vol. 31, no. 2, pp. 203–209, 1990. View at: Publisher Site | Google Scholar
  114. S. P. Hollinshead, M. L. Trudell, P. Skolnick, and J. M. Cook, “Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester,” Journal of Medicinal Chemistry, vol. 33, no. 3, pp. 1062–1069, 1990. View at: Publisher Site | Google Scholar
  115. J. M. Cook, H. Diaz-Arauzo, and M. S. Allen, “Inverse agonists: probes to study the structure, topology and function of the benzodiazepine receptor,” in Proceedings of the 51st Annual Scientific Meeting, L. S. Harris, Ed., National Institute on Drug Abuse Research Monograph, pp. 133–139, The College on Problems of Drug Dependence, 1991. View at: Google Scholar
  116. R. Trullas, H. Ginter, B. Jackson et al., “3-Ethoxy-beta-carboline: a high affinity benzodiazepine receptor ligand with partial inverse agonist properties,” Life Sciences, vol. 43, no. 15, pp. 1189–1197, 1988. View at: Publisher Site | Google Scholar
  117. M. Cain, R. W. Weber, F. Guzman et al., “β-Carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors,” Journal of Medicinal Chemistry, vol. 25, no. 9, pp. 1081–1091, 1982. View at: Publisher Site | Google Scholar
  118. X. H. He, C. C. Zhang, and J. M. Cook, “Model of the BzR binding site: correlation of data from site-directed mutagenesis and the pharmacophore/receptor model,” Medicinal Chemistry Research, vol. 10, no. 5, pp. 269–308, 2001. View at: Google Scholar
  119. Q. Huang, R. Y. Liu, P. W. Zhang et al., “Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [αxβ3γ2 (x = 1−3, 5, and 6)] via comparative molecular field analysis,” Journal of Medicinal Chemistry, vol. 41, no. 21, pp. 4130–4142, 1998. View at: Publisher Site | Google Scholar
  120. R. Y. Liu, P. W. Zhang, T. Gan, R. M. McKernan, and J. M. Cook, “Evidence for the conservation of conformational topography at five major GABA(A)/benzodiazepine receptor subsites. Potent affinities of the (S)-enantiomers of framework-constrained 4,5-substituted pyrroloimidazo-benzodiazepines,” Medicinal Chemistry Research, vol. 7, no. 1, pp. 25–35, 1997. View at: Google Scholar
  121. Q. Huang, W. Zhang, R. Liu, R. M. McKernan, and J. M. Cook, “Benzo-fused benzodiazepines employed as topological probes for the study of benzodiazepine receptor subtypes,” Medicinal Chemistry Research, vol. 6, no. 6, pp. 384–391, 1996. View at: Google Scholar
  122. S. Yu, X. H. He, C. R. Ma, R. McKernan, and J. M. Cook, “Studies in search of α2 selective ligands for GABAA/BzR receptor subtypes. Part I. Evidence for the conservation of pharmacophoric descriptors for DS subtypes,” Medicinal Chemistry Research, vol. 9, no. 3, pp. 186–202, 1999. View at: Google Scholar
  123. S. Arbilla, H. Depoortere, P. George, and S. Z. Langer, “Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 330, no. 3, pp. 248–251, 1985. View at: Publisher Site | Google Scholar
  124. G. Wong, K. F. Koehler, P. Skolnick et al., “Synthetic and computer-assisted analysis of the structural requirements for selective, high-affinity ligand binding to diazepam-insensitive benzodiazepine receptors,” Journal of Medicinal Chemistry, vol. 36, no. 13, pp. 1820–1830, 1993. View at: Publisher Site | Google Scholar
  125. A. Camerman and N. Camerman, “Stereochemical basis of anticonvulsant drug action. 2. Molecular structure of diazepam,” Journal of the American Chemical Society, vol. 94, no. 1, pp. 268–272, 1972. View at: Publisher Site | Google Scholar
  126. A. Hempel, N. Camerman, and A. Camerman, “Benzodiazepine stereochemistry: crystal structures of the diazepam antagonist Ro 15-1788 and the anomalous benzodiazepine Ro 5-4864,” Canadian Journal of Chemistry, vol. 65, no. 7, pp. 1608–1612, 1987. View at: Publisher Site | Google Scholar
  127. S. Neidle, G. D. Webster, G. B. Jones, and D. E. Thurston, “Structures of two DNA minor-groove binders, based on pyrrolo[2,1-c][1,4]-benzodiazepines,” Acta Crystallographica Section C: Crystal Structure Communications, vol. 47, no. 12, pp. 2678–2680, 1991. View at: Publisher Site | Google Scholar
  128. T. A. Halgren, “Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 616–641, 1996. View at: Google Scholar
  129. T. A. Halgren, “Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 553–586, 1996. View at: Publisher Site | Google Scholar
  130. T. A. Halgren, “Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 520–552, 1996. View at: Publisher Site | Google Scholar
  131. T. A. Halgren, “Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 490–519, 1996. View at: Publisher Site | Google Scholar
  132. T. A. Halgren and R. B. Nachbar, “Merck molecular force field. IV. Conformational energies and geometries for MMFF94,” Journal of Computational Chemistry, vol. 17, no. 5-6, pp. 587–615, 1996. View at: Google Scholar
  133. H. L. June, S. C. Harvey, K. L. Foster et al., “GABAAreceptors containing α5 subunits in the CA1 and CA3 hippocampal fields regulate ethanol-motivated behaviors: an extended ethanol reward circuitry,” Journal of Neuroscience, vol. 21, no. 6, pp. 2166–2177, 2001. View at: Google Scholar
  134. B. J. Kaminski, M. L. Van Linn, J. M. Cook, W. Yin, and E. M. Weerts, “Effects of the benzodiazepine GABAA α1-preferring ligand, 3-propoxy-β-carboline hydrochloride (3-PBC), on alcohol seeking and self-administration in baboons,” Psychopharmacology, vol. 227, no. 1, pp. 127–136, 2013. View at: Publisher Site | Google Scholar
  135. S. Huang, Synthesis of Optically Active Subtype Selective Benzodiazepine Receptor Ligands, University of Wisconsin, Milwaukee, Wis, USA, 2007.
  136. M. M. Savić, S. Majumder, S. Huang et al., “Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at α1 plus α5 versus α2 plus α3 subunits account for dissimilarities in behavioral effects in rats?” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 2, pp. 376–386, 2010. View at: Publisher Site | Google Scholar
  137. M. Ernst, D. Brauchart, S. Boresch, and W. Sieghart, “Comparative modeling of GABAA receptors: limits, insights, future developments,” Neuroscience, vol. 119, no. 4, pp. 933–943, 2003. View at: Publisher Site | Google Scholar
  138. B. L. Roth, “Ki determinations were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program,” Contract # HHSN-271-2013-00017-C (NIMH PDSP), The NIMH PDSP, 2013, https://pdspdb.unc.edu/pdspWeb/. View at: Google Scholar
  139. M. S. Choudhary, S. Craigo, and B. L. Roth, “Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors,” Molecular Pharmacology, vol. 42, no. 4, pp. 627–633, 1992. View at: Google Scholar
  140. J. Yang, Y. Teng, S. Ara, S. Rallapalli, and J. M. Cook, “An improved process for the synthesis of 4H-imidazo[1,5-a][1,4]benzo­diazepines,” Synthesis, no. 6, pp. 1036–1040, 2009. View at: Publisher Site | Google Scholar
  141. Z.-Q. Gu, G. Wong, C. Dominguez, B. R. De Costa, K. C. Rice, and P. Skolnick, “Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at ‘diazepam-insensitive’ benzodiazepine receptors,” Journal of Medicinal Chemistry, vol. 36, no. 8, pp. 1001–1006, 1993. View at: Publisher Site | Google Scholar
  142. J. Buckingham, Dictionary of Organic Compounds, vol. 2, Chapman & Hall, New York, NY, USA, 1982.
  143. C. Yung-Chi and W. H. Prusoff, “Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,” Biochemical Pharmacology, vol. 22, no. 23, pp. 3099–3108, 1973. View at: Publisher Site | Google Scholar
  144. J. M. Cook, T. Clayton, Y. T. Johnson, S. Rallapalli, and D. Han, “GABAergic agents to treat memory deficits,” US Patent 2010/0130479 A1, 2010. View at: Google Scholar

Copyright © 2015 Terry Clayton et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views4923
Downloads1169
Citations

Related articles